0HGLYDWLRQ,QF
&/,1,&$/5(6($5&+35272&2/
6WXG\7LWOH $3KDVH2SHQ/DEHO6LQJOH$UP6WXG\RI
)6RGLXP)OXRULGH3(7&7%RQH,PDJLQJLQ
(Q]DOXWDPLGH7UHDWHG&KHPRWKHUDS\1DwYH3DWLHQWV:LWK%RQH0HWDVWDWLF&DVWUDWLRQ5HVLVWDQW3URVWDWH&DQFHU
3URWRFRO,GHQWLILHU 0'9
3KDVH 
,QYHVWLJDWLRQDO3URGXFW (Q]DOXWDPLGHIRUPHUO\0'9 
,QGLFDWLRQ 3URVWDWH&DQFHU 
6SRQVRU 0HGLYDWLRQ,QFDZKROO\ RZQHGVXEVLGLDU\RI
3IL]HU,QF0DUNHW6WUHHWWK)ORRU6DQ)UDQFLVFR&$7HOHSKRQH )D[  
&RVSRQVRU 
86$
5HIHUHQFH1XPEHU 8QLWHG6WDWHV,1'
6SRQVRU0HGLFDO0RQLWRU 0'3K'
7HOHSKRQH 0RELOH (PDLO 
2ULJLQDO3URWRFRO YÂ±$8*
$PHQGPHQW YÂ±)(%
$PHQGPHQW YÂ±'(&
 
7KLVVWXG\ZLOOEHFRQGXFWHGDFFRUGLQJWRWKHSULQFLSOHVRI*RR G&OLQLFDO3UDFWLFHDVGHVFULEHGLQ
,QWHUQDWLRQDO&RXQFLOIRU+DUPRQLVDWLRQJXLGHOLQHVLQFOXGLQJW KHDUFKLYLQJRIHVVHQWLDOGRFXPHQWV
PPD
PPD
PPD
PPDPPD
0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
6<1236,6
7LWOHRI6WXG\ $3KDVH2SHQ/DEHO6LQJOH$UP6WXG\RI)6RGLXP)OXRULGH3(7&7%RQH,PDJLQJ
LQ(Q]DOXWDPLGH7UHDWHG&KHPRWKHUDS\1DwYH3DWLHQWV:LWK%RQH0 HWDVWDWLF&DVWUDWLRQ 5HVLVWDQW3URVWDWH
&DQFHU
3URWRFRO,GHQWLILHU 0'9
3KDVHRI'HYHORSPHQW 
1XPEHURI3DWLHQWV $SSUR[LPDWHO\
6WXG\&HQWHUV LQWKH8QLWHG6WDWHV86 
6WXG\2EMHFWLYHV
3ULPDU\
x(YDOXDWH)VRGLXPIOXRULGHSRVLWURQHPLVVLRQWRPRJUDSK\FRPSXWHGWRPRJ UDSK\)1D)3(7&7
LPDJLQJDVDPHWKRGIRUGHWHUPLQLQJWUHDWPHQWUHVSRQVHLQPHWDV WDWLFERQHOHVLRQVDWWKHWLPHRIGLVHDVH
SURJUHVVLRQSURVWDWHVSHFLILFDQWLJHQ>36$@ERQHRUVRIWWLVV XHRURWKHUFOLQLFDOO\UHOHYDQWSURJUHVVLRQ
RUDW\HDUVZLWKRXWSURJUHVVLRQDIWHUWUHDWPHQWLQLWLDWLRQLQ SDWLHQWVZKRDUHFKHPRWKHUDS\QDwYHLQWKH
FDVWUDWLRQUHVLVWDQWVHWWLQJZLW KSURJUHVVLYHERQHPHWDVWDWLFF DVWUDWLRQUHVLVWDQWSURVWDWHFDQFHU&53&
WUHDWHGZLWKHQ]DOXWDPLGH
6HFRQGDU\
x(YDOXDWHKHWHURJHQHLW\RIUHVSRQVHLQPHWDVWDWLFERQHOHVLRQVD WWKHWLPHWKHSULPDU\REMHFWLYHLVDVVHVVHG
0HWKRGV 7KLVSKDVHRSHQODEHOVLQJOHDUPVWXG\LQSDWLHQWVZKRDUH FKHPRWKHUDS\QDwYHLQWKH
FDVWUDWLRQUHVLVWDQWVHWWLQJZLWKSURJUHVVLYHERQHPHWDVWDWLF& 53&LVGHVLJQHGWRHYDOXDWH)1D)3(7&7
LPDJLQJDVDPHWKRGWRTXDQWLI\FKDQJHVLQWRWDOWXPRUEXUGHQL QERQHPHWDVWDVHVLQLQGLYLGXDOOHVLRQVDVZHOO
DVDFURVVDOOOHVLRQVDQGWKHKHWHURJHQHLW\RIUHVSRQVHLQWKR VHERQHOHVLRQVDIWHUWUHDWPHQWZLWKHQ]DOXWDPLGH
7KHSULPDU\HQGSRLQWLVWKHSURSRUWLRQRISDWLHQWVZLWKDWOHDV WUHVSRQGLQJERQHOHVLRQDWWKHWLPHRI36$
UDGLRJUDSKLFERQHRUVRIWWLVVXHRURWKHUFOLQLFDOO\UHOHYDQ WSURJUHVVLRQRUDW\HDUVZLWKRXWSURJUHVVLRQDIWHU
WUHDWPHQWLQLWLDWLRQ
7KHVWXG\ZLOOHQUROODSSUR[LPDWHO\SDWLHQWVDWVWXG\VLWH VLQWKH86)1D)3(7&7LPDJLQJZLOOEH
SHUIRUPHGGXULQJWKHVWXG\DVIROORZV
x1D) )ROORZLQJVFUHHQLQJEHIRUHILUVWGRVH
x1D) $WZHHN
x1D) $WWKHWLPHRI36$UDGLRJUDSKLFERQHRUVRIWWLVVXH RURWKHUFOLQLFDOO\UHOHYDQWSURJUHVVLRQ
 RUDW\HDUVZLWKRXWSURJUHVVLRQDIWHUWUHDWPHQWLQLWLDWLRQ
)ROORZLQJVFUHHQLQJLQFOXGLQJDP7F0'3ERQHVFLQWLJUDSK\HQUROOHGSDWLHQWVZLOOKDYHEDVHOLQH
)1D)3(7&7LPDJLQJ1D)DQGWKHQEHJLQRSHQODEHOWUHDWPHQ WZLWKHQ]DOXWDPLGHPJ
DGPLQLVWHUHGDVIRXUPJFDSVXOHVE\PRXWKRQFHGDLO\ CCI
0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
36$UHVSRQVHZLOOEHGHWHUPLQHGDWZHHNZKHQDVHFRQG)1D)3(7&7LPDJLQJ1D)LVREWDLQHG
3DWLHQWVZLWKDQ\LQFUHDVHLQ36$DWZHHNPD\GLVFRQWLQXHWU HDWPHQWDQGSURFHHGWRVDIHW\IROORZXSXQOHVV
WKHLQYHVWLJDWRUFRQVLGHUVFRQWLQXDWLRQRIVWXG\GUXJWREHEHQ HILFLDO)RUDOOFRQWLQXLQJSDWLHQWV36$ZLOOEH
PRQLWRUHGHYHU\ZHHNVDIWHUZHHNDQGRWKHUVWXG\DVVHVVPHQ WVZLOOFRQWLQXHWREHREWDLQHG$WKLUG
)1D)3(7&7LPDJLQJ1D)DQGDIROORZXSP7F0'3ERQHVFLQWLJUDSK\ZLOOEHSHUIRUPHGZKHQ
36$SURJUHVVLRQDQLQFUHDVHRIDWOHDVW$1'DQDEVROXWHLQ FUHDVHRIDWOHDVWQJP/DERYHQDGLU
UDGLRJUDSKLFSURJUHVVLRQERQHRUVRIWWLVVXHRURWKHUFOLQLF DOO\UHOHYDQWSURJUHVVLRQHJVLJQLILFDQWERQHSDLQ
RUDVNHOHWDOUHODWHGHYHQWLVREVHUYHGRUDW\HDUVZLWKRXW SURJUHVVLRQDIWHULQLWLDWLRQRIWUHDWPHQW1R
P7F0'3ERQHVFLQWLJUDSK\ZLOOEHU HTXLUHGDWWKHWLPHWKH1D) ERQHVFDQLVREWDLQHGLIERQHGLVHDVH
SURJUHVVLRQZDVFRQILUPHGHDUOLHURQERQHVFLQWLJUDSK\REWDLQHG DWLQYHVWLJDWRUGLVFUHWLRQ
%RQHGLVHDVHSURJUHVVLRQZLOOEHGHILQHGDVWKHDSSHDUDQFHRID WOHDVWQHZOHVLRQVDIWHUVFUHHQLQJDVVHVVHGE\
P7F0'3ERQHVFLQWLJUDSK\3URJUHVVLRQDWZHHNRUHDUOLHUZL OOUHTXLUHDFRQILUPDWRU\P7F0'3ERQH
VFLQWLJUDSK\DWOHDVWZHHNVOD WHUVKRZLQJDWOHDVWDGGLWLRQ DOQHZOHVLRQVUHO DWHGWRSURVWDWHFDQFHUFRPSDUHG
ZLWKWKHSUHYLRXVVFDQ$IWHUZHHNQRFRQILUPDWLRQRISUR JUHVVLRQZLOOEHUHTXLUHGLIDWOHDVWQHZOHVLRQV
UHODWHGWRSURVWDWHFDQFHUDUHREVHUYHG$VVHVVPHQWRIVRIWWL VVXHGLVHDVHZLOOEHE\&7RUPDJQHWLFUHVRQDQFH
LPDJLQJ05,REWDLQHGDWLQYHV WLJDWRUGLVFUHWLRQ5DGLRJUDSKL FSURJUHVVLRQIRUVRIWWLVVXHGLVHDVHZLOOEH
GHILQHGE\WKH5HVSRQVH(YDOXDWLR Q&ULWHULDLQ6ROLG7XPRUVYH UVLRQ5(&,67
7UHDWPHQWZLWKHQ]DOXWDPLGHPD\FRQWLQXHWKHUHDIWHUIRUDVORQJ DVWKHLQYHVWLJDWRUFRQVLGHUVLWEHQHILFLDO
&RQWLQXDWLRQRIHQ]DOXWDPLGHWUHDWPHQWLVVWURQJO\HQFRXUDJHGD WOHDVWWKURXJKFRPSOHWLRQRI1D)
%ORRGVDPSOHVZLOOEHFROOHFWHGD WEDVHOLQHDQGDWWKHWLPHRI WKHWKLUG)1D)3(7&7LPDJLQJIRUWKH
LVRODWLRQ 7KHVHFHOOVZLOOEHVWDLQHGIRUWKHDQGURJHQ
UHFHSWRUDQGJOXFRFRUWLFRLGUHFHS WRUDQGUHFHSWRUSURWHLQH[SU HVVLRQZLOOEHTXDQWLILHGXVLQJTXDQWLWDWLYH
LPPXQRF\WRFKHPLVWU\7KHVXEFHOOXODUORFDOL]DWLRQRIWKHVHUHF HSWRUVF\WRSODVPLFYVQXFOHDUZLOOEH
GHWHUPLQHG$GGLWLRQDOO\'1$DQG51$ZLOOEHH[WUDFWHGIURPU HFRYHUHGFLUFXODWLQJWXPRUFHOOVDQGVWRUHG
IRUSRWHQWLDOIXWXUHDQDO\VHVLIZDUUDQWHG
$OOSDWLHQWVDUHUHTXLUHGWRPDLQ WDLQFDVWUDWHOHYHOVRIWHVWRV WHURQHÂ”QPRO/GXULQJWKHVWXG\HLWKHUE\
UHFHLYLQJDOXWHLQL]LQJKRUPRQHUHOHDVLQJKRUPRQH/+5+DQDORJ XHRUE\SULRUELODWHUDORUFKLHFWRP\
7UHDWPHQWZLWKDELUDWHURQHDFHW DWHNHWRFRQD]ROHDPLQRJOXWHWKL PLGHUDGLXP5DGLFKORULGHRURWKHU
ERQHWDUJHWLQJUDGLRQXFOLGHVF\WRWR[LFFKHPRWKHUDS\LQWKH&53 &VHWWLQJUDGLDWLRQWKHUDS\WRERQHRURWKHU
H[SHULPHQWDOWKHUDSLHVIRUWKHWUHDWPHQWRIFDQFHULVSURKLELWH GGXULQJWKHVWXG\EHIRUH1D),QLWLDWLRQRI
ELVSKRVSKRQDWHVRUGHQRVXPDEIRUDQ\UHDVRQLVQRWDOORZHGKRZ HYHUWUHDWPHQWZLWKWKHVHDJHQWVPD\
FRQWLQXHLILQLWLDWHGDWOHDVWZHHNVEHIRUHHQUROOPHQW6WDQ GDUGRIFDUHVXSSOHPHQWDWLRQZLWKFDOFLXPDQG
YLWDPLQ'LVHQFRXUDJHG
$VVHVVPHQWVRIVDIHW\ZLOOLQFOXGHDGYHUVHHYHQWVFOLQLFDOODE RUDWRU\WHVWVSK\VLFDOH[DPLQDWLRQVDQGYLWDO
VLJQV3DWLHQWVZLOOKDYHVDIHW \IROORZXSDSSUR[LPDWHO\GD \VDIWHUWKHODVWGRVHRIVWXG\GUXJRUEHIRUH
LQLWLDWLRQRIF\WRWR[LFFKHPRWKHUDS\DOXWDPLGHELFDOXWDPLGH QLOXWDPLGHRUIOXWDPLGHRUDQHZ
LQYHVWLJDWLRQDOWKHUDS\ZKLFKHYHURFFXUVILUVW 
6WXG\6FKHPDWLF 
 (Q]DOXWDPLGHPJGD\
)1D)
3(7&7
&7&)1D)
3(7&7)1D)
3(7&7
&7&
P7F0'3
ERQH
VFLQWLJUDSK\6DIHW\
IROORZXSaGD\V
DIWHUODVWGRVH 1D)
3UHGRVH
ZLWKLQGD\V1D) 1D)
6DIHW\
IROORZXS36$
P7F0'3
ERQH
VFLQWLJUDSK\,QLWLDWH
WUHDWPHQW(YDOXDWH
36$
UHVSRQVH'D\ :HHN:HHN
DQGTZHHNV
)ROORZIRU
36$
SURJUHVVLRQ,QYHVWLJDWRU
FRQVLGHUV
HQ]DOXWDPLGH
WREHQRORQJHU
EHQHILFLDO6FUHHQLQJ3URJUHVVLRQ
RU
\HDUVZLWKQR
SURJUHVVLRQDIWHU
WUHDWPHQWLQLWLDWLRQ
36$
UDGLRJUDSKLF ERQHRUVRIWWLVVXH RU
FOLQLFDOO\UHOHYDQW HJVLJQLILFDQWERQH
SDLQRUVNHOHWDOUHODWHGHYHQW
CCI
0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
.H\(OLJLELOLW\&ULWHULD
3DWLHQWVPXVWKDYHERQHPHWDVWDWLF&53&DVDVVHVVHGE\DWOHDVW OHVLRQVRQFRQYHQWLRQDOZKROHERG\
P7F0'3UDGLRQXFOLGHERQHVFLQWLJUDSK\WKDWGLGQRWVKRZDVXSHU VFDQ3DWLHQWVZLWKYLVFHUDOPHWDVWDWLF
GLVHDVHDUHH[FOXGHG7KH\PXVWKDYHSURJUHVVLYHGLVHDVHRQDQ GURJHQGHSULYDWLRQWKHUDS\DWVFUHHQLQJ
GHILQHGDVDPLQLPXPRIVHTXHQWLDOO\ULVLQJ36$YDOXHV36$ 36$36$DVVHVVHGE\WKHORFDO
ODERUDWRU\ZLWKDQLQWHUYDORIÂ•ZHHNEHWZHHQHDFKGHWHUPLQDW LRQ7KHPRVWUHFHQW36$PXVWEHÂ•Â—J/
Â•QJP/3DWLHQWVPXVWDJUHHWRFRQWLQXHDQGURJHQGHSULYDW LRQWKHUDS\ZLWKDQ/+5+DQDORJXHWKURXJKRXW
WKHVWXG\RUKDYHKDGDSULRUELODWHUDORUFKLHFWRP\7HVWRVWHU RQHDWVFUHHQLQJPXVWEHÂ”QPRO/
Â”QJG/$GGLWLRQDOO\SDWLHQWVPXVWKDYHDV\PSWRPDWLFRU PLQLPDOO\V\PSWRPDWLFSURVWDWHFDQFHU%ULHI
3DLQ,QYHQWRU\6KRUW)RUPTXHVWLRQVFRUHZLWKRXWXVHRI RSLDWHDQDOJHVLFVIRUSURVWDWHFDQFHUSDLQZLWKLQ
ZHHNVEHIRUHHQUROOPHQWGD\DQ(DVWHUQ&RRSHUDWLYH2QFRO RJ\*URXS(&2*SHUIRUPDQFHVFRUHÂ”
DQGDQHVWLPDWHGOLIHH[SHFWDQF\RIÂ•PRQWKVDWVFUHHQLQJ 3ULRUHQ]DOXWDPLGHDELUDWHURQHDFHWDWH
DPLQRJOXWHWKLPLGHNHWRFRQD]ROHUDGLXP5DGLFKORULGHRURW KHUERQHWDUJHWLQJUDGLRQXFOLGHVF\WRWR[LF
FKHPRWKHUDS\LQWKH&53&VHWWLQJIRUWKHWUHDWPHQWRISURVWDWH FDQFHUDQGSDUWLFLSDWLRQLQ DFOLQLFDOWULDORIDQ
LQYHVWLJDWLRQDODJHQWWKDWLQKLELWVWKHDQGURJHQUHFHSWRURUDQ GURJHQV\QWKHVLVXQOHVVWUHDWPHQWZDVSODFHER
DUHSURKLELWHG3DWLHQWVZLWKDKLVWRU\RIVHL]XUHDQ\WLPHLQ WKHSDVWIRUDQ\UHDVRQRUDQ\FRQGLWLRQWKDWPD\
SUHGLVSRVHWRVHL]XUHDUHH[FOXGHG
7HVW3URGXFW'RVHDQG0RGHRI$GPLQLVWUDWLRQ (Q]DOXWDPLGHFKHPLFDOQDPH^>F\DQR
WULIOXRURPHWK\OSKHQ\O@GLPHWK\OR[RVXOIDQ\OLGHQHLPLG D]ROLGLQ\O`IOXRUR 1PHWK\OEHQ]DPLGH
(Q]DOXWDPLGHPJGD\ZLOOEHDGPLQLVWHUHGDVIRXUPJVRIW JHODWLQFDSVXOHVE\PRXWKRQFHGDLO\ZLWKRU
ZLWKRXWIRRG
5HIHUHQFH7KHUDS\'RVHDQG0R GHRI$GPLQLVWUDWLRQ 1RQH
'XUDWLRQRI7UHDWPHQW 3DWLHQWVZLOOUHFHLYHHQ]DOXWDPLG HWUHDWPHQWGDLO\DVGHILQHGL Q0HWKRGV$IWHU
1D)LVFRPSOHWHGDQRWKHUWKHUDS\PD\EHDGGHGWRHQ]DOXWDPLG HDVORQJDVLWLVQRWDQRWKHUDQGURJHQ
UHFHSWRULQKLELWRUF\WRWR[LFFKH PRWKHUDS\RUDQLQYHVWLJDWLRQ DOGUXJ3DWLHQWVPD\FRQWLQXHWRUHFHLYH
WUHDWPHQWZLWKHQ]DOXWDPLGHIRUDVORQJDVWKHLQYHVWLJDWRUFRQ VLGHUVLWEHQHILFLDO
6WDWLVWLFDO0HWKRGV
7KHVWXG\HQGSRLQWVDUHDVIROORZV
3ULPDU\
x7KHSURSRUWLRQRISDWLHQWVZLWKDWOHDVWUHVSRQGLQJERQHOHVL RQGHILQHGDVDOHVLRQZLWKDWRWDO
VWDQGDUGL]HGXSWDNHYDOXH>689 WRWDO@OHVVWKDQWKDWDWEDVHOLQHRQWKHWKLUG)1D)3(7&7>1D)@VFDQ
SHUIRUPHGIRUHDFKSDWLHQW7KLVDVVHVVPHQWZLOOEHWULJJHUHG E\GLVHDVHSURJUHVVLRQDVGHILQHGLQ
0HWKRGVRUDW\HDUVZLWKRXWSURJUHVVLRQDIWHUWUHDWPHQWLQLW LDWLRQ
6HFRQGDU\
x7KHKHWHURJHQHLW\RIUHVSRQVHDFURVVDOOERQHOHVLRQVDVGHWHUP LQHGE\WKHJOREDOKHWHURJHQHLW\RI1D)
VWDQGDUGL]HGXSWDNHYDOXH689 KHWHURZKHQWKHSULPDU\HQGSRLQWLVGHWHUPLQHGIRUHDFKSDWLHQW
CCI
0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
7KHSULPDU\HIILFDF\HQGSRLQWDQDO\VLVZLOOLQFOXGHSDWLHQWVZK RXQGHUJRDWOHDVW1D)DQG1D)
)1D)3(7&7LPDJLQJ'HILQLWLRQVRIWKH1D)XSWDNHPHDVXUHVD UHDVIROORZV
x689WRWDO 7RWDO1D)XSWDNHZKLFKUHSUHVH QWVWKHWXPRUEXUGHQDFURVVDOO JOREDOERQHOHVLRQVRULQ
 LQGLYLGXDOOHVLRQV
x689KHWHUR +HWHURJHQHLW\RI1D)XSWDNHZKLFKUHSUHVHQWVKHWHURJHQHLW\RI OHVLRQDFWLYLW\
x689PHDQ 0HDQ1D)XSWDNHZKLFKUHSUHVHQWVWKHDYHUDJHDFWLYLW\RIDOO OHVLRQV
x689PD[ 0D[LPXP1D)XSWDNHZKLFKUHSUHVHQWVWKHDFWLYLW\RIWKHPRVW DJJUHVVLYHOHVLRQ
x1 7RWDOQXPEHURIOHVLRQVZKLFKUHSUHVHQWVDQXPHULFDOVXPRI DOOOHVLRQV
x9) 9ROXPHIUDFWLRQZKLFKUHSUHVHQWVWKHIUDFWLRQRIVNHOHWDOL QYROYHPHQW 
7KHJOREDO689 KHWHURVFRUHLVDPHDVXUHRIWKHKHWHURJHQHLW\RIWXPRUDFWLYLW\DFUR VVDOOERQHOHVLRQVDQGLV
GHILQHGDVIROORZVZKHUH J JOREDO O OHVLRQ 1 QXPEHURIERQHOHVLRQV

,QRWKHUZRUGVWKHJOREDO689 KHWHURVFRUHLVWKHVXPRIWKHVTXDUHVRIWKHGLIIHUHQFHVEHWZHHQWKH 689PHDQIRU
HDFKERQHOHVLRQDQGWKHJOREDO689 PHDQGLYLGHGE\WKHQXPEHURIOHVLRQV7KXVDKLJKHUJOREDO689 KHWHUR
VFRUHUHIOHFWVPRUHKHWHURJHQHLW\LQERQHOHVLRQDFWLYLW\
&LUFXODWLQJWXPRUFHOOV
$QGURJHQUHFHSWRUDQGJOXFRFRUWLFRL GUHFHSWRUVXEFHOOXODUORFDO L]DWLRQDQGH[SUHVVLRQ &LUFXODWLQJWXPRU
FHOOVZLOOEHFROOHFWHGDWEDVHOLQHDQG1D)6WDQGDUGGHVFUL SWLYHVWDWLVWLFVZLOOEH FDOFXODWHGQPHDQ
VWDQGDUGGHYLDWLRQPHGLDQDQGUDQJH DVZHOODVIRU
DQGURJHQUHFHSWRUDQGJOXFRFRUWLFRLGUHFHSWRUVXEFHOOXODUH[SUH VVLRQDQGORFDOL]DWLRQF\WRSODVPLFYVQXFOHDU
&RUUHODWLRQRIFLUFXODWLQJWXPRUFHOODQDO\VHVZLWK1D)XSWDNH PHDVXUHVDQGFOLQLFDORXWFRPHV  


7KHODERUDWRU\PDQXDOKDVLQVWUXFWLRQVIRUWKHH[WUDFWLRQDQGV WRUDJHRI51$VDPSOHVIRURWKHUDQDO\VHVWKDW
PD\EHSHUIRUPHGLQWKHIXWXUHLIZDUUDQWHG CCI
CCI
CCI
CCI
Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 6 of 66 
Safety : 
All safety analyses will be based on the safety population, defined as all patients who receive any amount of 
study drug.   
Safety will be evaluated by the incidence of serious adverse events, incidence and severity of adverse events, 
incidence of study drug discontinuation due to adverse events, and incidence of new clinically significant 
changes in clinical laboratory values and vital signs.   
All adverse events will be coded and tabulated by system organ class and preferred term using the Medi cal 
Dictionary for Regulatory Activities (MedDRA).  The number and percentage of patients with treatment -emergent adverse events will be presented by MedDRA system organ class and preferred term, 
relationship to study treatment, and severity.  Descriptive statistics will be used.   
Laboratory values will be classified for severity using the National Cancer Institute Common Terminology Criteria for Adverse Events, version  4.  Laboratory shift tables of baseline results to each subsequent visit will 
be produc ed as appropriate.   
Sample Size Considerations:  
The total number of patients to be included in this study is approximately  20 and is based on practical clinical 
considerations.   
 

0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
7$%/(2)&217(176
6<1236,6    
/,672)$%%5(9,$7,216$1'7(506    
 ,1752'8&7,21    
 %DFNJURXQG    
 6XPPDU\RI5HOHYDQW&OLQLFDO([SHULHQFH:LWK(Q]DOXWDPLGH   
  3KDUPDFRNLQHWLFVDQG'UXJ0HWDEROLVP   
 6XPPDU\RI5HOHYDQW1RQFOLQLFDO([SHULHQFH:LWK(Q]DOXWDPLGH   
 (Q]DOXWDPLGH%HQHILWVDQG5LVNV$VVHVVPHQW   
 678'<2%-(&7,9(6    
 3ULPDU\2EMHFWLYH    
 6HFRQGDU\2EMHFWLYH    
 ,19(67,*$7,21$/3/$1    
 2YHUDOO6WXG\'HVLJQDQG3ODQ'HVFULSWLRQ   
 6WXG\6FKH PDWLF    
 %OLQGLQJ    
 'XUDWLRQRI6WXG\    
 'LVFXVVLRQRI6WXG\'HVLJQ,QFOXGLQJ&KRLFHRI&RQWURO*URXS   
 6(/(&7,212)678'<3238/$7,21   
 ,QFOXVLRQ&ULWHULD    
 ([FOXVLRQ&ULWHULD    
 (152//0(17$1'678' <352&('85(6   
 6FUHHQLQJ3HULRG    
  6WXG\,GHQWLILFDWLRQ1XPEHUV   
  6FUHHQLQJ9LVLW3URFHGXUHV   
 7UHDWPHQW3HULRG    
  9LVLW:LQGRZV    
  :HHN'D\    
  :HHN    
  :HHN    
  :HHNDQG5HSHDWLQJ(YHU\:HHNV   
  7LPHRI7KLUG)1D)3(7&7,PDJLQJ1D)   
  8QVFKHGXOHG9LVLWV   
 3HUPDQHQW7UHDWPHQW'LVFRQWLQXDWLRQ   
 6DIHW\)ROORZ8S    
 /RVVWR)ROORZ8S    
 ,19(67,*$7,21$/352'8&7,1)250$7,21   
 *HQHUDO,QIRUPDWLRQ    
 (Q]DOXWDPLGH3URGXFW&KDUDFWHULVWLFV    
  3DFNDJLQJRI(Q]DOXWDPLGH   
  6WRUDJHRI(Q]DOXWDPLGH   
  'LUHFWLRQVIRU$GPLQLVWUDWLRQRI(Q]DOXWDPLGH   
  'LUHFWLRQVIRU'RVH0RGLILFDWLRQRI(Q]DOXWDPLGH   
 7UHDWPHQW&RPSOLDQFH    
 35,25$1'&21&20,7$177+(5$3<   
 3ULRU7KHUDS\    
 &RQFRPLWDQW7KHUDS\    CCI
0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
 3RWHQWLDO,QWHUDFWLRQV%HWZHHQWKH7HVW3URGXFWVDQG&RQFRPLWDQ W0HGLFDWLRQV  
  (Q]DOXWDPLGH    
  (IIHFWVRI(Q]DOXWDPLGHRQ([SRVXUHWR2WKHU'UXJV   
  'UXJV7KDW0D\$IIHFW([SRVXUHWR(Q]DOXWDPLGH   
 3UHFDXWLRQV5HJDUGLQJ&RQFRPLWDQW0HGLFDWLRQV   
 6$)(7<&216,'(5$7,216    
 6DIHW\0RQLWRULQJ    
 6SHFLDO6DIHW\&RQVLGHUDWLRQV    
  6WXG\'UXJ'RVH0RGLILFDWLRQ'XHWR$GYHUVH(YHQW   
  2YHUGRVH0DQDJHPHQW   
  &RQWUDFHSWLRQ    
 $GYHUVH(YHQW'HILQLWLRQVDQG5HSRUWLQJ   
  $GYHUVH(YHQW'HILQLWLRQV   
  $GYHUVH(YHQW5HSRUWLQJ   
  $GYHUVH(YHQW5HSRUWLQJ3HULRGV   
  $VVHVVPHQWRI&DXVDO5HODWLRQVKLS   
  $VVHVVPHQWRI6HYHULW\,QWHQVLW\   
  6HULRXV$GYHUVH(YHQWDQG(YHQWRI6SHFLDO,QWHUHVW5HSRUWLQJ   
  &ODULILFDWLRQLQ5HSRUWLQJRI6HL]XUHV   
  &ODULILFDWLRQLQ5HSRUWLQJRI'HDWKV   
  &ODULILFDWLRQLQ5HSRUWLQJRI'LV HDVH3URJUHVVLRQDVDQ$GYHUVH (YHQW  
  )ROORZ8SRI6HULRXVDQG1RQVHULRXV$GYHUVH(YHQWV   
  3UHJQDQF\5HSRUWLQJ3URFHGXUH   
 &OLQLFDO/DERUDWRU\6DIHW\7HVWV    
 3K\VLFDO([DPLQDWLRQV9LWDO6LJQVDQG(OHFWURFDUGLRJUDPV   
 $66(660(172)()),&$&<$1'6$)(7<(1'32,176   
 $VVHVVPHQWRI(IILFDF\    
  $VVHVVPHQWVIRUWKH3ULPDU\DQG6HFRQGDU\(IILFDF\(QGSRLQWV   
  )1D)3(7&7,PDJLQJ   
  $VVHVVPHQWRI'LVHDVH3URJUHVVLRQ   
 (&2*3HUIRUPDQFH6WDWXV$VVHVVPHQWV   
 67$7,67,&$/0(7+2'6$1'6$03/(6,=('(7(50,1$7,21   
 6WDWLVWLFDODQG$QD O\WLFDO3ODQV    
 $QDO\VLV3RSXODWLRQV    
 (IILFDF\$QDO\VHV    
  3ULPDU\(IILFDF\(QGSRLQW$QDO\VLV   
  6HFRQGDU\(IILFDF\(QGSRLQW$QDO\VLV   
 6DIHW\$QDO\VHV    
 2WKHU$QDO\VHV    CCI
CCI
Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 9 of 66 
10.6 Determination of Sample Size  .......................................................................................................... 53 
11 STUDY COMMITTEES AND  COMMUNICATIONS  .......................................................................... 53 
12 LABORATORY REQUIREME NTS  ....................................................................................................... 53 
13 INVESTIGATOR AND ADM INISTRATIVE REQUIREM ENTS  ...................................................... 54 
13.1 Ethics  ................................................................................................................................................ 54 
13.1.1  Institutional Review Board ................................................................................................. 54 
13.1.2  Ethical Conduct of the Study  ............................................................................................. 55 
13.1.3  Patient Information and Informed Consent  ........................................................................ 55 
13.1.4  Maintaining Patient Confidentiality  ................................................................................... 55 
13.2 Data Quality Assurance  .................................................................................................................... 55 
13.2.1  Data Management  .............................................................................................................. 55 
13.2.2  Case Report Forms  ............................................................................................................. 56 
13.2.3  Study Monitoring  ............................................................................................................... 56 
13.2.4  Study Audits  ....................................................................................................................... 56 
13.3 Investigational Product Accountability  ............................................................................................ 57 
13.4 Compensation, Insurance, and Indemnity ........................................................................................ 58 
13.5 Retention of Records  ........................................................................................................................ 58 
13.6 Study Termination  ............................................................................................................................ 58 
14 USE OF STUDY INFORMATION AND PUBLICATION  ................................................................... 59 
15 REFERENCES  ........................................................................................................................................... 61 
16 INVESTIGATO R SIGNATURE  .............................................................................................................. 62 

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 10 of 66 
LIST OF TABLES  
Table  1: Screening Procedures  .................................................................................................................... 25 
Table  2: Week  1, Day  1 Procedures ............................................................................................................. 27 
Table  3: Week  5 Procedures  ........................................................................................................................ 28 
Table  4: Week  13 Procedures  ...................................................................................................................... 29 
Table  5: Week  21 and Repeating Every 8  Weeks Procedures  ..................................................................... 30 
Table  6: Time of Third 18F-NaF PET/CT Imaging (NaF -3) ........................................................................ 31 
Table  7: Unscheduled Visit Procedures  ....................................................................................................... 32 
Table  8: Safety Follow -Up Procedures  ........................................................................................................ 34 
Table  9: Criteria for Serious Adverse Events  .............................................................................................. 41 
Table  10: Criteria for Determining Causal Relationship to Study Drug  ........................................................ 43 
Table  11: Criteria for Determining the Severity (Intensity) of an Adverse Event  ......................................... 43 
Table  12: Clinical Laboratory Safety Tests  ................................................................................................... 46 
Table  13: ECOG Performance Statu s Assessments  ....................................................................................... 49 
Table  14: Definition of Terms for NaF Uptake Measures  ............................................................................. 50 
 
LIST OF FIGURES  
Figure  1: Study Schematic  ............................................................................................................................ 20 
 
LIST OF APPENDICES  
Appendix  1: Brief Pain Inventory (Short Form) ................................................................................................. 63 
Appendix  2: Study Schedule of Activities  ......................................................................................................... 65 
 

0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
/,672)$%%5(9,$7,216$1'7(506
$EEUHYLDWLRQ 'HILQLWLRQ
$/7 $ODQLQHDPLQRWUDQVIHUDVH
$67 $VSDUWDWHDPLQRWUDQVIHUDVH
$8& $UHDXQGHUWKHFXUYH$8&
Â’ $UHDXQGHUWKHFXUYHIURPWLPH]HURWRLQILQLW\
&)5 &RGHRI)HGHUDO5HJXODWLRQV
&PD[ 0D[LPXPSODVPDFRQFHQWUDWLRQ
&53& &DVWUDWLRQUHVLVWDQWSURVWDWHFDQFHU
&7 &RPSXWHGWRPRJUDSK\&7&$( &RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV&
WURXJK 3UHGRVHWURXJKSODVPDFRQFHQWUDWLRQ
&<3 &\WRFKURPH3
' &KDQJH
Ç»689WRWDO &KDQJHLQWRWDO1D)XSWDNH
(&* (OHFWURFDUGLRJUDP(&2* (DVWHUQ&RRSHUDWLYH2QFRORJ\*URXS
)1D))VRGLXPIOXRULGH
)'$ )RRGDQG'UXJ$GPLQLVWUDWLRQ*&3 *RRG&OLQLFDO3UDFWLFH
+5 +D]DUGUDWLR,&+ ,QWHUQDWLRQDO&RXQFLOIRU+DUPRQLVDWLRQ
,' ,GHQWLILFDWLRQ
,15 ,QWHUQDWLRQDOQRUPDOL]HGUDWLR
,5% ,QVWLWXWLRQDOUHYLHZERDUG/+5+ /XWHLQL]LQJKRUPRQHUHOHDVLQJKRUPRQH0HG'5$ 0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV05, 0DJQHWLFUHVRQDQFHLPDJLQJ1D)
)1D)3(7&7IROORZLQJVFUHHQLQJEHIRUHILUVWGRVH
1D))1D)3(7&7DWZHHN
1D))1D)3(7&7DWWKHWLPHRIGLVHDVHSURJUHVVLRQRUDW\HDUVZ LWKRXWSURJUHVVLRQ
DIWHUWUHDWPHQWLQLWLDWLRQ
3(7 3RVLWURQHPLVVLRQWRPRJUDSK\
3. 3KDUPDFRNLQHWLF36$ 3URVWDWHVSHFLILFDQWLJHQ
5(&,67 5HVSRQVH(YDOXDWLRQ&U LWHULDLQ6ROLG7XPRUVYHUVLR Q
686$5 6XVSHFWHGXQH[SHFWHG VHULRXVDGYHUVHUHDFWLRQ
689 6WDQGDUGL]HGXSWDNHYDOXH
689
PHDQ 0HDQ1D)XSWDNH
689WRWDO 7RWDO1D)XSWDNHCCI
Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 12 of 66 
Abbreviation  Definition  
SUV hetero Heterogeneity of NaF uptake  
99mTc-MDP  Technetium Tc 99m medronate  
ULN  Upper limit of normal  
US United States  

0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
,1752'8&7,21
%DFNJURXQG
5HFXUUHQFHRISURVWDWHFDQFHUGXULQJOXWHLQL]LQJKRUPRQHUHOHDV LQJKRUPRQH/+5+
DQDORJXHWKHUDS\RUDIWHUDELODWH UDORUFKLHFWRP\DVGHWHFWHG E\SURVWDWHVSHFLILFDQWLJHQ
36$RUUDGLRJUDSKLFSURJUH VVLRQVLJQDOVWUDQVLWLRQWRWKHOH WKDOSKHQRW\SHRI
FDVWUDWLRQUHVLVWDQWSURVWDWH FDQFHU&53&36$SURJUHVVLRQD ORQHPD\SUHGLFWODWHU
UDGLRJUDSKLFSURJUHVVLRQZKLFK IUHTXHQWO\HQWDLOVWKHGHYHORSP HQWRUZRUVHQLQJRIH[LVWLQJ
ERQHPHWDVWDVHVWKDWFDQOHDGW RVSLQDOFRUGFRPSUHVVLRQSDWKR ORJLFIUDFWXUHDQGWKHQHHG
IRUQHZWUHDWPHQWPHDVXUHVVSDQQLQJPXOWLSOHPRGDOLWLHVVXUJLF DOUDGLRORJLF
SKDUPDFRORJLF'HSHQGLQJRQWKHH[WHQWRIGLVHDVHDQGV\PSWRP DWRORJ\SDWLHQWVZLWKVXFK
GLVHDVHSURJUHVVLRQPD\WKHQUHF HLYHQHZKRUPRQDOHQ]DOXWDPLGH DELUDWHURQH
LPPXQRORJLFVLSXOHXFHO7UDGLRORJLFUDGLXP5DGLFKORULG HRUF\WRWR[LFGRFHWD[HO
WKHQFDED]LWD[HOWKHUDS\2IQRW H/+5+DQDORJXHWKHUDS\LVD OPRVWDOZD\VFRQWLQXHG
ZKHQSURVWDWHFDQFHUEHFRPH VFDVWUDWLRQUHVLVWDQW
)VRGLXPIOXRULGHSRVLWURQHPL VVLRQWRPRJUDSK\FRPSXWHGWRPRJ UDSK\ERQHLPDJLQJ
)1D)3(7&7SUHGDWHVFRQYHQWL RQDOWHFKQHWLXP7FPPHGURQDWH P7F0'3ERQH
VFLQWLJUDSK\DQGLVPRUHVHQVLWLYHDQGVSHFLILFLQLGHQWLI\LQJ ERQHPHWDVWDVHV8VHRI
)1D)3(7&7DWVHOHFWDFDGHPLFFHQWHUVLQWKH8QLWHG6WDWHV8 6RIIHUVWKHRSSRUWXQLW\
WRWHVWWKHK\SRWKHVLVWKDWFRQWLQXLQJHQ]DOXWDPLGHPD\EHRIW KHUDSHXWLFEHQHILWIRUWKH
WUHDWPHQWRIERQHPHWDVWD VHVDIWHU36$RUUDG LRJUDSKLFSURJUHVV LRQLQFOXGLQJ
FRQYHQWLRQDOO\GHILQHGERQHRUV RIWWLVVXHGLVHDVHSURJUHVVLRQ 
7KLVSKDVHRSHQODEHOVW XG\RIHQ]DOXWDPLGHZLOOGHWHUPLQHW KHSURSRUWLRQRISD WLHQWVZLWK
DWOHDVWUHVSRQGLQJPHWDVWDWLF ERQHOHVLRQDQGWKHKHWHURJHQH LW\RIUHVSRQVHDFURVVDOOERQH
OHVLRQVIRUSDWLH QWVZKRKDYH)1D)3(7&7ERQHLPDJL QJDWWKHWLPHRI36$
UDGLRJUDSKLFERQHRUVRIWWLVVX HRURWKHUFOLQLFDOO\UHOHYDQ WSURJUHVVLRQHJVLJQLILFDQW
ERQHSDLQRUDVNHOHWDO UHODWHGHYHQWRUDW\HDUVZLWKRXWS URJUHVVLRQDIWHULQLWLDWLRQRI
HQ]DOXWDPLGHWUHDWPHQW
6XPPDU\RI5HOHYDQW&OLQLFDO( [SHULHQFH:LWK( Q]DOXWDPLGH
7KH86)RRGDQG'UXJ$GPLQLVWUD WLRQ)'$DSSURYHG;WDQGLHQ]D OXWDPLGHFDSVXOHVLQ
$XJXVWEDVHGRQDEHQHILWLQRYH UDOOVXUYLYDOIRUPHQZLWK PHWDVWDWLF&53&ZKR
SUHYLRXVO\UHFHLYHGGRFHWD[HOWKHUDS\ ;WDQGLZDVODWHUDSSURYH GLQ&DQDGDWKH(XURSHDQ
8QLRQDQGRWKHUFRXQWULHVIRUXV HLQWKLVSDWLHQWSRSXODWLRQ 
0HGLYDWLRQ ,QFDUHLQD SDUWQHUVKLSWRFRGHYHORS
HQ]DOXWDPLGHIRUWKHWU HDWPHQWRIFDQFHUPPD
0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
7KHNH\FOLQLFDOVWXGLHVHYDOXD WLQJHQ]DOXWDPLGHLQPHQZLWKPH WDVWDWLF&53& DUHGHVFULEHG
EULHIO\DVIROORZV
&53&$)),50$SKDVHUD QGRPL]HGGRXEOHEOLQGSODFHERF RQWUROOHGHIILFDF\
DQGVDIHW\VWXG\RIHQ]DOXWDPLG HPJGDLO\LQSDWLHQWVZLW KSURJUHVVLYH&53&
SUHYLRXVO\WUHDWHGZLWKGRFHWD[ HOEDVHGFKHPRWKHUDS\ZDVFRQGXF WHGLQPHQ
RIZKRPUHFHLYHGWUHDWPH QWZLWKHQ]DOXWDPLGH7KHSULPDU\HQGSRL QWZDVRYHUDOO
VXUYLYDO7KHSUHVSHFLILHGLQW HULPDQDO\VLVDWWKHWLPHRI HYHQWVGHPRQVWUDWHG
DVWDWLVWLFDOO\VLJQLILFDQWLPS URYHPHQWLQRYHUDOOVXUYLYDOLQ SDWLHQWVWUHDWHGZLWK
HQ]DOXWDPLGHYHUVXVSODFH ER+5>&,@S &XUUHQW
PDUNHWLQJDSSOLFDWL RQDSSURYDOVIRUPHQZ LWKPHWDVWDWLF&53&ZK RKDYHSUHYLRXVO\
UHFHLYHGGRFHWD[HOWKHUDS\DUHED VHGRQWKHUHVXOWVRIWKLVSLY RWDOVWXG\
0'935(9$,/$SKDV HUDQGRPL]HGGRXEOHEOLQGSOD FHERFRQWUROOHG
HIILFDF\DQGVDIHW\VWXG\RIHQ] DOXWDPLGHPJGDLO\LQFKH PRWKHUDS\QDwYHSDWLHQWV
ZLWKSURJUHVVLYHPHWDVWDWLFSURV WDWHFDQFHUZKRKDYHIDLOHGDQG URJHQGHSULYDWLRQ
WKHUDS\ZDVFRQGXFWHGLQP HQRIZKRPUHFHLYHGWUHDWPH QWZLWK
HQ]DOXWDPLGH7KHFRSULPDU\H QGSRLQWVZHUHRYHUDOOVXUYLYDODQ GUDGLRJUDSKLF
SURJUHVVLRQIUHHVXUYLYDO7KHSUHV SHFLILHGLQWHULPDQDO\VLVD WWKHWLPHRIGHDWK
HYHQWVGHPRQVWUDWHGVWDWLVWLFDOO\VLJQLILFDQWLPSURYHPHQWVLQR YHUDOOVXUYLYDODQG
UDGLRJUDSKLFSURJUHVVLRQIUHHVX UYLYDOLQSDWLHQWVWUHDWHGZLWK HQ]DOXWDPLGHYHUVXV
SODFHER(Q]DOXWDPLGHWUHDWPHQW UHVXOWHGLQSURORQJDWLRQRIRY HUDOOVXUYLYDO+5
>&,@SDQGUDG LRJUDSKLFSURJUHVVLRQ IUHHVXUYLYDO+5
>&,@S
,QDGGLWLRQWRWKHFOLQLFDOVWXGL HVLQPHQZLWKPHWDVWDWLF&53& DNH\FOLQLFDOVWXG\
HYDOXDWHGHQ]DOXWDPLGHPRQRWKH UDS\LQPHQZLWKKRUPRQHVHQVLWLY HSURVWDWHFDQFHU
DVIROORZV
&/$SKDVHRSHQODEHO VLQJOHDUPPXOWLFHQWHU HIILFDF\DQGVDIHW\
VWXG\RIHQ]DOXWDPLGHPRQRWKH UDS\PJGDLO\LQSDWLHQWV ZLWKKRUPRQHQDwYH
SURVWDWHFDQFHUIRUZKRPDQGURJH QGHSULYDWLRQWKHUDS\ZDVLQGLF DWHG7KHSULPDU\
REMHFWLYHZDVWRGHWHUPLQHWKHLQ FLGHQFHRISDWLHQWVZLWKDÂ• 36$UHVSRQVHDW
ZHHN6HFRQGDU\REMHFWLYHVLQF OXGHGHYDOXDWLRQRIVDIHW\DQ GWROHUDELOLW\

,QWKHSKDVHVWXG\&53&$)),501 WKHPRVWFRPPRQ DGYHUVHGUXJUHDFWLRQV
tLQSDWLHQWVWUHDWHGZLWKHQ] DOXWDPLGH1 ZHUHDVWKH QLDIDWLJXHEDFNSDLQ
GLDUUKHDDUWKUDOJLDKRWIOXVKSH ULSKHUDOHGHPDPXVFXORVNHOH WDOSDLQKHDGDFKHXSSHU
UHVSLUDWRU\LQIHFWLRQPXVFXODU ZHDNQHVVGL]]LQHVVLQVRPQLD ORZHUUHVSLUDWRU\LQIHFWLRQ
VSLQDOFRUGFRPSUHVVLRQDQGFDXGD HTXLQDV\QGURP HKHPDWXULDS DUHVWKHVLDDQ[LHW\DQG
K\SHUWHQVLRQ'LVFRQWLQXDWLRQVGXH WRDGYHUVHHYHQWVZHUHUHSR UWHGIRURI
HQ]DOXWDPLGHWUHDWHGSDWLHQWV DQGRISODFHER WUHDWHGSDWLHQ WV7KHPRVWFRPPRQCCI
Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 15 of 66 
adverse reaction leading to treatment discontinuation was seizure, which occurred in 
7 (0.9%) of the enzalutamide -treated patients and none (0%) of the placebo -treated patients.   
In the phase 3 study MDV3100- 03 (PREVAIL; N  = 1715), enzalutamide was generally well 
tolerated with an overall safety profile consistent with that observed in study CRPC2 , with 
a lower seizure rate observed in MDV3100-03 (1 patient [0.1%] each in the enzalutamide and placebo treatment groups).  The new adverse drug reactions observed in study MDV3100-03, gynecomastia and restless legs syndrome, were uniformly nonserious events occurring at low frequency (3.3% and 2.1%, respectively, in e nzalutamide -treated patients 
vs 1.3% and 0.4%, respectively, in placebo- treated patients).   
In the phase 2 study 9785- CL-0321, enzalutamide monotherapy was well tolerated.  Most 
common treatment- emergent adverse events were grade 1, and included gynecomastia (36%), 
fatigue (34%), nipple pain (19%), and hot flush (18%).  Five patients had serious adverse events; none of the events were assessed as related to enzalutamide treatment.  Mean changes from baseline for fasting metabolic variables were +5.0% total cholesterol, +8.9% triglycerides, â€“3.5% hemoglobin A
1c, and +19.7% insulin resistance (homeostasis model 
assessment -estimated insulin resistance; HOMA -IR).  Total body bone mineral density was 
maintained ( â€“0.3% from baseline).  Quality of life scores at 1 year demonstrated maintenance 
of global health status, and decreased sexual activity and sexual functioning.   
Additional information on the clinical experience with enzalutamide is provided in the 
Enzalutamide Investigator Brochure .   
1.2.1 Pharmacokinetics and Drug Metabolism  
In pharmacokinetics (PK) investigations in men with CRPC, enzalutamide was absorbed rapidly after oral administration, with the time to maximum plasma concentration (t
max) after 
a single dose typically occurring at 1  hour postdose.  At steady state, enzalutamide showed 
approximately dose proportional PK over the daily dose range of 30 to 360 mg.  Due to the long terminal half -life (approximately  5.8 days), it  took approximately 1 month to reach 
steady state.  With daily oral administration, enzalutamide accumulation was observed at steady state with an 8.3 -fold higher exposure (steady- state area under the curve, AUC) 
relative to a  single dose.  Based on the me an peak -to-trough ratio, the average difference 
between the peak (maximum plasma concentration, C
max) and trough (predose plasma 
concentration, C trough) concentrations was â‰¤ 25%.  As a result of the low daily fluctuations, 
plasma profiles at steady state resembled a constant infusion.  The C trough values in individual 
patients remained constant beyond day 28 of chronic therapy, suggesting time- linear PK once 
steady state was achieved.  At steady state, plasma concentrations of enzalutamide and the active metabolite, N -desmethyl enzalutamide, were approximately the same.   
In a drug -drug interaction study in male patients with CRPC (9785 -CL-0007), a single oral 
dose of a subs trate for cytochrome  P450 (CYP) 2C8, CYP2C9, CYP2C19, or CYP3A4 was 
administered before and concomitantly with enzalutamide (after at least 55  days of dosing at 
160 mg daily).  Enzalutamide at steady state reduced the plasma exposure to midazolam (CYP3A 4 substrate), warfarin (CYP2C 9 substrate), and omeprazole (CYP2C19 substrate) 
administer ed orally by 86%, 56%, and 70%, respectively.  Based on the magnitude of the 

0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
GHFUHDVHVLQH[SRVXUHHQ]DOXW DPLGHLVFRQVLGHUHGDVWURQJLQGX FHURI&<3$DQG
DPRGHUDWHLQGXFHUR I&<3&DQG&<3& 6HFWLRQ 2UDOO\DGPLQLVWHUHG
VXEVWUDWHVRI&<3$ &<3&DQG&<3&ZLW KDQDUURZWKHUDSH XWLFLQGH[VKRXOGEH
DYRLGHGLISRVVLEOHDVHQ]DOXWD PLGHPD\GHFUHDVHSODVPDH[SRVX UHRIWKHVHGUXJV,I
HQ]DOXWDPLGHLVFRDGPLQLVWHUHGZ LWKZDUIDULQ&<3&VXEVWUDWH DGGLWLRQDOLQWHUQDWLRQDO
QRUPDOL]HGUDWLR,1 5PRQLWRULQJVKRXOGEHFRQGXFWHG(Q]DOXW DPLGHGLGQRWFDXVH
FOLQLFDOO\PHDQLQJIXOFKDQJHVL QH[SRVXUHWRSL RJOLWD]RQH&<3 &VXEVWUDWH
,QDGUXJGUXJLQWHUDFWLRQVWXG\ LQKHDOWK\PDOHYROXQWHHUV &/DVLQJOHPJ
RUDOGRVHRIHQ]DOXWDPLGHZDVDG PLQLVWHUHGDORQHRUDIWHUPXOWL SOHRUDOGRVHVRIJHPILEUR]LO
VWURQJ&<3&LQKLELWRU 



7KHHIIHFWVRI&<3 &LQGXFHUVRQWKH3.
RIHQ]DOXWDPLGHKDYHQRW EHHQHYDOXDWHGLQYLYR 6HFWLRQ 
,QWKHGUXJGUXJLQWHUDFWLRQVWXG\LQKHDOWK\PDOHYROXQWHHUV &/DVLQJOH
PJRUDOGRVHRIHQ]DOXWDPLGH ZDVDGPLQLVWHUHGDORQHRUDIWH UPXOWLSOHRUDOGRVHVRI
LWUDFRQD]ROHVWURQJ& <3$LQKLELWRU 


7KHHIIHFWVRI&<3$LQGXFHUV
RQWKH3.RIHQ]DOXWDPLGHKD YHQRWEHHQHYDOXDWHGLQYLYR 6HFWLRQ 
$GGLWLRQDOLQIRUPDWLRQRQWKH3. DQGGUXJPHWDEROLVPRIHQ]DOXW DPLGHLVSURYLGHGLQWKH
(Q]DOXWDPLGH,QYHVWLJDWRU%URFKXUH
6XPPDU\RI5HOHYDQW1RQFOLQLFDO ([SHULHQFH:LWK (Q]DOXWDPLGH
$FRPSOHWHDVVHVVPHQWRIWR[LFLW \KDVEHHQFRQGXFWHGZLWKHQ]DO XWDPLGHLQFOXGLQJ
HYDOXDWLRQRILPSXULWLHV7KHWR[LF LW\SURJUDPZDVGHVLJQHGWR VXSSRUWWUHDWPHQWRIPHQ
ZLWK&53&DQGLQFOXGH GDFXWHVLQJOHGRVHDQGUHSHDWGRVHXS WRZHHNVGXUDWLRQLQ
UDWVDQGZHHNVLQGRJVRUDO WR[LFLW\VWXGLHVJHQRWR[LF LW\VWXGLHVVDIHW\
SKDUPDFRORJ\VWXGLHVV SHFLILFDVVHVVPHQW RIWKHHIIHFWVRQDQG UHFRYHU\RIWKHPDOH
UHSURGXFWLYHV\VWHPLQGRJVDQGV WXGLHVWRGHWHUPLQHWKHSKRWR WR[LFLW\SRWHQWLDO7KH
VSHFLHVLQFOXGHGLQWKHWR[LFLW\SU RJUDPZHUHPLFHUDWVGRJV DQGF\QRPROJXVPRQNH\V
7R[LFRNLQHWLFHYDOXDWL RQVGHPRQVWUDWHGWKDW DOORIWKHVHVSHFLH VSURGXFHWKHPDMRUKXPDQ
PHWDEROLWHVRIHQ]DOXW DPLGH1GHVPHWK\OH Q]DOXWDPLGHDQGDQLQ DFWLYHFDUER[\OLFDFLG
GHULYDWLYH7KHWR[LF RORJLFSURILOHRI1GHV PHWK\OHQ]DOXWDPLG HDSSHDUVWREHYHU\VLPLODU
WRHQ]DOXWDPLGH
7KHWR[LFLW\VWXGLHVWHVWHGHQ]DO XWDPLGHIRUPXODWHGLQ/DEUDVRO WKHVDPHH[FLSLHQWXVHGLQ
FOLQLFDOVWXGLHVDQGLQWKHFRPPH UFLDOSURGXFWP DUNHWHGIRU&53 &CCI
CCI
Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 17 of 66 
Long -term animal studies have not been conducted to evaluate the carcinogenic potential of 
enzalutamide.   
Enzalutamide did not induce mutations in the bacterial reverse mut ation (Ames) assay and 
was not genotoxic in either the in vitro cytogenetic assay with mouse lymphoma thymidine 
kinase gene mutation or the in vivo mouse micronucleus assay.   
Based on nonclinical findings in repeat-dose toxicity studies, which were consistent with the 
pharmacologic activity of enzalutamide, male fertility may be impaired by treatment with 
enzalutamide.  In a 26- week study in rats, atrophy of the prostate and seminal vesicles was 
observed at â‰¥  30 mg/kg/day (equal to the human exposure based on AUC).  In 4-week and 
13-week studies in dogs, hypospermatogenesis and atrophy of the prostate and epididymides 
were observed at â‰¥ 4 mg/kg/day (0.3-times the human exposure based on AUC).   
Additional toxicity studies are ongoing and planned.  Additional information on the 
nonclinical experience with enzalutamide is provided in the Enzalutamide Investigator 
Brochure .   
1.4 Enzalutamide Benefits and Risks Assessment  
Approximately 5000 subjects and patients have been enrolled worldwide in completed and ongoing clinical trials evaluating enzalutamide.  Approximately 3200 have received at  least 
1 dose of enzalutamide.  Available data for enzalutamide in men with metastatic prostate cancer that has progressed despite therap y with an LHRH analogue or bilateral orchiectomy 
support a positive benefit- risk profile for the use of enzalutamide as an investigational agent 
in this study, which will enroll patients similar to those  who participated in MDV3100-03, 
with the caveat that patients must have bone metastatic disease to enter this study .  The 
clinical experience with enzalutamide is discussed  briefly in Section  1.2.   
2 STUDY OBJECTIVES  
2.1 Primary Objective  
â€¢ Evaluate 18F-NaF PET/CT imaging as a  method for determining treatment response in 
metastatic bone lesions at the time of disease progression (PSA, bone or soft tissue, or 
other clinically relevant progression) or at 2 years without progression after treatment 
initiation in patients who are chemotherapy -naÃ¯ve in the castration -resistant setting 
with progressive bone- metastatic CRPC treated with enzalutamide  
2.2 Secondary Objective  
â€¢ Evaluate heterogeneity of response in metastatic bone lesions at the time the primary 
objective is assessed  

0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
,19(67,*$7,21$/3/$1
2YHUDOO6WXG\'HVLJQDQG3ODQ'HVFULSWLRQ
7KLVSKDVHRSHQODEHOVLQJOHDU PVWXG\LQSDWLHQWVZKRDUH FKHPRWKHUDS\QDwYHLQWKH
FDVWUDWLRQUHVLVWDQWVHWWLQJZ LWKSURJUHVVLYHERQHPHWDVWDWLF& 53&LVGHVLJQHGWRHYDOXDWH
)1D)3(7&7LPDJLQJDVDPHW KRGWRTXDQWLI\FKDQJHVLQWRWDOW XPRUEXUGHQLQERQH
PHWDVWDVHVLQLQGLYLGXDOOHVLRQVD VZHOODVDFURVVDOOOHVLRQV DQGWKHKHWHURJHQHLW\RI
UHVSRQVHLQWKRVHERQHOHVLRQVDIW HUWUHDWPHQWZLWKHQ]DOXWDPL GH7KHSULPDU\HQGSRLQWLV
WKHSURSRUWLRQRISDWLHQW VZLWKDWOHDVWUHVSRQGLQJERQHOHVL RQDWWKHWLPHRI36$
UDGLRJUDSKLFERQHRUVRIWWLVVX HRURWKHUFOLQLFDOO\UHOHYDQ WSURJUHVVLRQRUDW\HDUV
ZLWKRXWSURJUHVVLRQDIWHU WUHDWPHQWLQLWLDWLRQ
7KHVWXG\ZLOOHQUROODSSUR[LPDWHO\SDWLHQWVDWVWXG\VLWH VLQWKH86)1D)3(7&7
LPDJLQJZLOOEHSHUIRUPHGGXULQJWKHVWXG\DVIROORZV
x1D) )ROORZLQJVFUHHQLQJEHIRUHILUVWGRVH
x1D) $WZHHN
x1D) $WWKHWLPHRI36$UDGLRJU DSKLFERQHRUVRIWWLVVXH RURWKHUFOLQLFDOO\
 UHOHYDQWSURJUHVVLRQRUDW\H DUVZLWKRXWSURJUHVVLRQDIWHU WUHDWPHQW
 LQLWLDWLRQ
)ROORZLQJVFUHHQLQJLQFOXGLQJDP7F0'3ERQHVFLQWLJUDSK\H QUROOHGSDWLHQW VZLOOKDYH
EDVHOLQH)1D)3(7&7LPDJLQJ1D) DQGWKHQEHJLQRSHQ ODEHOWUHDWPHQ WZLWK
HQ]DOXWDPLGHPJDGPLQLVWHUH GDVIRXUPJFDSVXOHVE\PR XWKRQFHGDLO\36$
UHVSRQVHZLOOEHGHWHUPLQHG DWZHHNZKHQDVHFRQG)1D)3(7&7LPDJLQJ1D)LV
REWDLQHG3DWLHQWVZLWKDQ\LQF UHDVHLQ36$DWZHHNPD\GLV FRQWLQXHWUHDWPHQWDQG
SURFHHGWRVDIHW\IROORZXSXQOHVV WKHLQYHVWLJDWRUFRQVLGHUVF RQWLQXDWLRQRIVWXG\GUXJWREH
EHQHILFLDO)RUDOOFRQWLQXLQJ SDWLHQWV36$Z LOOEHPRQLWRUHG HYHU\ZHHNVDIWHUZHHN
DQGRWKHUVWXG\DVVHVVPHQWVZ LOOFRQWLQXHWREHREWDLQHG$WK LUG)1D)3(7&7LPDJLQJCCI
0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
1D)DQGDIROORZXSP7F0'3ERQHVFLQWLJUDSK\ ZLOOEHSHUIRUPHGZKHQ
36$SURJUHVVLRQDQLQFUHDVHRID WOHDVW$1'DQDEVROXWHLQ FUHDVHRIDWOHDVWQJP/
DERYHQDGLUUDGLRJUDSKLFSURJ UHVVLRQERQHRUVRIWWLVVXHR URWKHUFOLQLFDOO\UHOHYDQW
SURJUHVVLRQHJVLJQLILFDQWERQHSD LQRUDVNHOHWDOUHODWHGHY HQWLVREVHUYHGRUDW\HDUV
ZLWKRXWSURJUHVVLRQDIWHULQ LWLDWLRQRIWUHDWPHQW1RP7F0'3ERQHVFLQWLJUDSK\ZLOOEH
UHTXLUHGDWWKHWLPHWKH1D) ERQHVFDQLVREW DLQHGLIERQHGL VHDVHSURJUHVVLRQZDV
FRQILUPHGHDUOLHURQERQ HVFLQWLJUDSK\REWDLQHGDWLQYHVWLJDWRU GLVFUHWLRQ
%RQHGLVHDVHSURJUHVVLRQZLOOEH GHILQHGDVWKHDSSHDUDQFHRID WOHDVWQHZOHVLRQVDIWHU
VFUHHQLQJDVVHVVHGE\P7F0'3ERQHVFLQWLJUDSK\3URJU HVVLRQDWZHHNRUHDUOLHUZL OO
UHTXLUHDFRQILUPDWRU\P7F0'3ERQHVFLQWLJUDSK\DWOHDVW ZHHNVODWHUVKRZLQJDWOHDV W
DGGLWLRQDOQHZOHVLRQVUHODWH GWRSURVWDWHFDQFHUFRPSDUHGZ LWKWKHSUHYLRXVVFDQ$IWHU
ZHHNQRFRQILUPDWLRQRISURJUH VVLRQZLOOEHUHTXLUHGLIDW OHDVWQHZOHVLRQVUHODWHGWR
SURVWDWHFDQFHUDUHREVHUYHG$VVH VVPHQWRIVRIWWLVVXHGLVHDV HZLOOEHE\&7RUPDJQHWLF
UHVRQDQFHLPDJLQJ05,REWDLQH GDWLQYHVWLJDWRUGLVFUHWLRQ5 DGLRJUDSKLFSURJUHVVLRQIRU
VRIWWLVVXHGLVHDVHZLOOEHGHIL QHGE\WKH5HVSRQVH(YDOXDWLRQ &ULWHULDLQ6ROLG7XPRUV
YHUVLRQ5(&,67
7UHDWPHQWZLWKHQ]DOXWDPLGHPD\F RQWLQXHWKHUHDIWHUIRUDVORQJ DVWKHLQYHVWLJDWRU
FRQVLGHUVLWEHQHILFLDO&RQWL QXDWLRQRIHQ]DOXW DPLGHWUHDWPHQ WLVVWURQJO\HQFRXUDJHGDW
OHDVWWKURXJKFRPSOHWLRQRI1D)
%ORRGVDPSOHVZLOOEHFROOHFWHGD WEDVHOLQHDQGDWWKHWLPHRI WKHWKLUG)1D)3(7&7
LPDJLQJIRUWKHL VRODWLRQ 7KHVH
FHOOVZLOOEHVWDLQHGI RUWKHDQGURJHQUHFHSWRUDQGJOXFRFRUWLF RLGUHFHSWRUDQGUHFHSWRU
SURWHLQH[SUHVVLRQZLOOEHTXDQ WLILHGXVLQJTXDQWLWDWLYHLPPXQR F\WRFKHPLVWU\7KH
VXEFHOOXODUORFDOL]DWLRQRIWKH VHUHFHSWRUVF\WRSODVPLFYVQXF OHDUZLOOEHGHWHUPLQHG
$GGLWLRQDOO\'1$DQG51$ZLOOEH H[WUDFWHGIURPUHFRYHUHGFLUF XODWLQJWXPRUFHOOVDQG
VWRUHGIRUSRWHQWLDOIXWXUHD QDO\VHVLIZDUUDQWHG
$OOSDWLHQWVDUHUHTXLUHGWRPDLQW DLQFDVWUDWHOHYHOVRIWHVWRV WHURQHÂ”QPRO/GXULQJWKH
VWXG\HLWKHUE\UHFHLYLQJDQ/+5 +DQDORJXHRUE\SULRUELODWHUD ORUFKLHFWRP\7UHDWPHQW
ZLWKDELUDWHURQHDFHWDWHNHWRFRQD]ROHDPLQRJOXWHWKLPLGHUDGL XP5DGLFKORULGHRU
RWKHUERQHWDUJHWLQJUDGLRQXFOLGHV F\WRWR[LFFKHPRWKHUDS\LQW KH&53&VHWWLQJUDGLDWLRQ
WKHUDS\WRERQHRURWKHUH[SHULPHQW DOWKHUDSLHVI RUWKHWUHDWP HQWRIFDQFHULVSURKLELWHG
GXULQJWKHVWXG\EHIRUH1D) ,QLWLDWLRQRIELVSKRVSKRQDWHVR UGHQRVXPDEIRUDQ\UHDVRQLV
QRWDOORZHGKRZHYHUWUHDWPHQWZLW KWKHVHDJHQWVPD\FRQWLQXH LILQLWLDWHGDWOHDVWZHHNV
EHIRUHHQUROOPHQW
6WDQGDUGRIFDUHVXSSOHPHQWDWL RQZLWKFDOFLXPDQGYLWDPLQ'LV HQFRXUDJHG
$VVHVVPHQWVRIVDIHW\ZLOOLQFOXGHDGYHUVHHYHQWVFOLQLFDOODE RUDWRU\WHVWVSK\VLFDO
H[DPLQDWLRQVDQGYLWDOVLJQV3 DWLHQWVZLOOKDYHVDIHW\IROOR ZXSDSSUR[LPDWHO\GD\V
DIWHUWKHODVWGRVHRIVWXG\G UXJRUEHIRUHLQLWLDWLRQRIF\WRW R[LFFKHPRWKHUDS\DOXWDPLGH
ELFDOXWDPLGHQLOXWD PLGHRUIOXWDPLGHRU DQHZLQYHVWLJDWLR QDOWKHUDS\ZKLFKHYHURFFXUV
ILUVWCCI
0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
7KHVWXG\VFKHPDWLFLVSURYLGHGLQ )LJXUH
6WXG\6FKHPDWLF
)LJXUH 6WXG\6FKHPDWLF

%OLQGLQJ
7UHDWPHQWZLWKHQ]DOXWD PLGHZLOOEHRSHQODEHO
'XUDWLRQRI6WXG\
7KHWRWDOGXUDWLRQRIWKLVVWXG \ZLOOEHDSSUR[LPDWHO\PRQWK VWRDFFRPPRGDWH1D)
LQSDWLHQWVZLWKRXWSURWRFROG HILQHGGLVHDVHSURJUHVVLRQ
'LVFXVVLRQRI6WXG\'HVLJQ,QF OXGLQJ&KRLFHRI&RQWURO*URXS
(Q]DOXWDPLGHLVK\SRWKHVL]HGWR FDXVHDQRQJRLQJWUHDWPHQWUHVS RQVHLQERQHPHWDVWDVHVDV
GHWHFWHGE\)1D)3(7&7LPDJLQJDWWKHWLPH RIFRQYHQWLRQDOO\GHILQHGGLVH DVH
SURJUHVVLRQLQSURJUHVVLYHERQHPHW DVWDWLF&53&.H\IHDWXUHV RIWKHVWXG\GHVLJQLQFOXGH
)1D)3(7&7LPDJLQJDWEDVHOLQ HDQGZHHNZKHQSDWLHQWVZLW KRXWD36$UHVSRQVH
PD\H[LWWKHVWXG\DQGDWW KHWLPHRIGLVHDVHSURJUHVVLRQZKH QQHZWUHDWPHQWVDUHRIWHQ
LQWURGXFHG1D)PHDVXUHPHQWVDW WKHVHWLPHSR LQWVDUHEDVHG RQWKHVWDQGDUGL]HGXSWDNH
YDOXH689WKHUDWLRRIWLVVXH UDGLRDFWLYLW\FRQFHQWUDWLRQWR WKHWRWDOLQMHFWHGDFWLYLW\SHU
SDWLHQWPDVVOHDQERG\PDVVRUERG\VXUIDFHDUHD 


7KLVRSHQODEHOVLQJOHDUPQRF RQWUROJURXSVWXG\LVGHVLJQH GWRGHWHUPLQHWKHSURSRUWLRQ
RISDWLHQWVZLWKDWOHDVWERQH OHVLRQUHVSRQGLQJWRHQ]DOXWDP LGHWUHDWPHQWLQSDWLHQWVZKR(Q]DOXWDPLGHPJGD\
)1D)
3(7&7
&7&)1D)
3(7&7)1D)
3(7&7
&7&
P7F0'3
ERQH
VFLQWLJUDSK\6DIHW\
IROORZXSaGD\V
DIWHUODVWGRVH 1D)
3UHGRVH
ZLWKLQGD\V1D) 1D)
6DIHW\
IROORZXS36$
P7F0'3
ERQH
VFLQWLJUDSK\,QLWLDWH
WUHDWPHQW(YDOXDWH
36$
UHVSRQVH'D\ :HHN:HHN
DQGTZHHNV
)ROORZIRU
36$
SURJUHVVLRQ,QYHVWLJDWRU
FRQVLGHUV
HQ]DOXWDPLGH
WREHQRORQJHU
EHQHILFLDO6FUHHQLQJ3URJUHVVLRQ
RU
\HDUVZLWKQR
SURJUHVVLRQDIWHU
WUHDWPHQWLQLWLDWLRQ
36$
UDGLRJUDSKLF ERQHRUVRIWWLVVXH RU
FOLQLFDOO\UHOHYDQW HJVLJQLILFDQWERQH
SDLQRUVNHOHWDOUHODWHGHYHQW
CCI
0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
KDYH)1D)3(7&7LPDJLQJZKHQGLVHDVHSURJUHVVLRQRFFXUV36$UDGL RJUDSKLF>ERQHRU
VRIWWLVVXH@RURWKHUFOLQLFDOO\ UHOHYDQWSURJUHVVLRQRUZKR DUHSURJUHVVLRQIUHH\HDUVDIWHU
LQLWLDWLRQRIWUHDWPHQW 7KHKHWHURJHQHLW\RIUHVSRQVHDFURVV DOOERQHOHVLRQVZLOODOVREH
GHWHUPLQHGD WWKLVWLPH
P7F0'3ERQHVFLQWLJUDSK\ZLOOEH XVHGWRTXDOLI\SDWLHQWVIRUW KHVWXG\DQGZLOOEH
UHSHDWHGDW1D)H[FHSWL QFDVHVRIERQHGLVHDVHSURJUHVVLRQ FRQILUPHGHDUOLHUWRVWXG\WKH
UHODWLRQVKLSEHWZHHQFRQYHQWLRQD OO\GHILQHGERQHGLVHDVHSURJUH VVLRQDQGPHDVXUHVRIERQH
WXPRUDFWLYLW\RQ)1D)3(7&7LPDJLQJLQFOXGLQJ WKHFKDQJHÇ»LQWRWDO689
Ç»689 WRWDODQGWKHKHWHURJHQHLW\RI1D)XSWDNH689 KHWHUR 

$GGLWLRQDOO\
'1$DQG51$ZLOOEHFROOHFWHGDQGV WRUHGIRUSRWHQWLDOIXWXUHD QDO\VHVHJDQDO\VLVRI
DQGURJHQUHFHSWRUPXWDWLRQVDQGV SOLFHYDULDQWVLIZDUUDQWHG 
7KHVWXG\SRSXODWLRQZLOOEHFRP SRVHGRIPHQZLWKKLVWRORJLFDOO \RUF\WRORJLFDOO\FRQILUPHG
DGHQRFDUFLQRPDRIWKHSURVWDWHZ LWKRXWQHXURHQGRFULQHGLIIHUHQW LDWLRQRUVLJQHW FHOORUVPDOO
FHOOIHDWXUHVDVUHVSRQVLYHQHVV WRHQGRFULQHWKHUDS\KDVEHHQ EHVWGHPRQVWUDWHGLQ
DGHQRFDUFLQRPDRIWKHSURVWDWHZ LWKRXWWKHVHIHD WXUHV4XDOLI\ LQJSDWLHQWVZ LOOKDYHERQH
PHWDVWDWLFGLVHDVHDVDVVHV VHGE\DWOHDVWOHVLRQVRQP7F0'3ERQHVFLQWLJUDSK\WKDWGLG
QRWVKRZDVXSHUVFDQWRHQDEOHWK HSRWHQWLDOGHPRQVWUDWLRQRI GLVFRUGDQFHLQWUHDWPHQW
UHVSRQVHDFURVVDJLYHQSDWLH QWÂ¶VERQHOHVLRQVRYHUWLPHDQGWR HQDEOHGHWH UPLQDWLRQRI
FRQYHQWLRQDOO\GHILQHGERQHGL VHDVHSURJUHVVLRQ7KXVSDWLHQW VZLOOVHUYHDVWKHLURZQ
FRQWUROV
3DWLHQWVZLOOQHHGWRGHPRQVWUDW HSURJUHVVLYHGLVHDVHRQDQGURJ HQGHSULYDWLRQWKHUDS\DW
VFUHHQLQJGHILQHGDVDPLQLPXPRI VHTXHQWLDOO\ULVLQJ36$YDO XHV36$36$36$
WRHQVXUHWKHLQFOXVLRQRISDWLHQW VZKRVHGLVHDVHLVGULYHQE\ VLJQDOLQJWKURXJKWKHDQGURJHQ
D[LVSDWKZD\3DWLHQWVZLOODO VRQHHGWRPDLQWDLQDQGURJHQGHS ULYDWLRQWKHUDS\ZLWKDQ
/+5+DQDORJXHWKURXJKRXWWKHV WXG\RUKDYHKDGD SULRUELODWHUD ORUFKLHFWRP\)LQDOO\
SDWLHQWVHYHUSUHYLRXVO\WUHDWH GZLWKHQ]DOXWDPLGHDELUDWHURQH DFHWDWHDPLQRJOXWHWKLPLGH
NHWRFRQD]ROHUDGLXP5DGLFK ORULGHRURWKHUERQHWDUJHWLQJ UDGLRQXFOLGHWKHUDS\
F\WRWR[LFFKHPRWKHUDS\LQWKH&53&VHWWLQJRULQYHVWLJDWLRQDO DJHQWVWKDWLQKLELWWKH
DQGURJHQUHFHSWRURUDQGURJHQV \QWKHVLVZLOOEHSURKLELWHGIURP SDUWLFLSDWLQJGXHWRWKH
XQNQRZQORQJWHUPHIIHFWVRI WKHVHWUHDWPHQWVRQ)1D)3(7&7LPDJLQJ
6(/(&7,212)678'<3238/$7,21
7KHVSHFLILFHOLJLELOLW\FULWHUL DIRUVHOHFWLRQRISDWLHQWVDUH SURYLGHGLQ 6HFWLRQ DQG
6HFWLRQ 7KHVSRQVRUZLOOQRWJUDQWDQ\ HOLJLELOLW\ZDLYHUVCCI
Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 22 of 66 
4.1 Inclusion Criteria  
Each patient  eligible to participate in this study must meet all of the following criteria:   
1. Age 18 years or older and willing and able to provide informed consent.   
2. Histologically or cytologically confirmed adenocarcinoma of the prostate without 
neuroendocrine differentiation, or signet cell or small cell features.   
3. Ability to comply with all study procedures and willingness to remain supine for 30 minutes during imaging.   
4. Presence of bone metastatic disease as assessed by at least 2  lesions on whole-body 
radionuclide 
99mTc-MDP  bone scintigraphy .   
5. Throughout the study, ongoing androgen deprivation therapy with an LHRH analogue or 
prior bi lateral orchiectomy (medical or surgical castration) .   
6. Testosterone â‰¤ 1.73 nmol/L (â‰¤ 50 ng/dL) at screening .   
7. Progressive disease on androgen deprivation therapy at screening defined as a minimum of 2 sequentially rising PSA values (PSA1 < PSA2  < PSA3) a ssessed by the local 
laboratory with an interval of â‰¥ 1 week between each determination  where PSA3  (the 
screening PSA) is obtained within 4  weeks before planned enrollment.   
8. The screening PSA (PSA3) must be â‰¥ 2 Âµg/L (â‰¥  2 ng/mL).  In the event of prior androgen 
receptor inhibitor use, the screening PSA must be obtained at least 4 weeks after the last dose of the androgen receptor inhibitor.   
9. Asymptomatic or minimally symptomatic prostate cancer (Brief Pain Inventory Short Form question 3 score < 4) at screening .   
10. Eastern Cooperative Oncology Group ( ECOG) performance status of 0  or 1 at screening .   
11. Estimated life expectancy of â‰¥  12 months at screening.   
12. Ability to swallow study capsules after a picture to scale of the capsules is shown to the 
patient and to comply with study requirements throughout the study.   
13. Throughout the study, patient and his female partner who is of childbearing potential 
must use 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception) from screening through 3 months after last dose of 
study drug.  Two acceptable methods of birth control thus include the following: 
â€¢ A condom (barrier method of contraception) 
AND 
â€¢ One of the following is required: 
â€“ Established and ongoing use of oral, injected, or implanted hormonal method of 
contraception by the female partner  
â€“ Placement of an intrauterine device or intrauterine system by the female partner  
â€“ Additional barrier method:  Contraceptive sponge or occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/suppository by the female partner  
â€“ Tubal ligation in the female partner performed at least 6  months before screening 
â€“ Vasectomy or other procedur e resulting in infertility (eg,  bilateral orchiectomy), 
performed at least 6 months before screening  

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 23 of 66 
14. Throughout the study, the patient must use a condom if having sex with a pregnant 
woman .   
15. Must agree not to donate sperm from first dose of study drug  through 3 months after the 
last dose of study drug.   
4.2 Exclusion Criteria  
Each patient  eligible to participate in this study must NOT meet any of the following 
exclusion criteria:   
1. Prior enzalutamide, abiraterone acetate, aminoglutethimide, ketoconazole, radium Ra 223 
dichloride or other bone- targeting radionuclides , or cytotox ic chemotherapy in the CRPC 
setting for the treatment of prostate cancer or participation in a clinical trial of an 
investigational agent that inhibits the androgen receptor or androgen synthesis (unless 
treatment was placebo) .   
2. Treat ment with hormonal therapy (eg,  androgen receptor inhibitors, 5- alpha reductase 
inhibitors) or biologic therapy for prostate cancer (other than LHRH analogue therapy) 
within 4  weeks before day  1.   
3. Initiation of new treatment with denosumab, bisphosphonates, or systemic corticosteroids for treatment of prostate cancer within 4  weeks before day  1.   
4. Use of an investigational agent within 4 weeks before the screening visit .  
5. Radiation therapy to bone within 4 weeks before day 1.   
6. Use of opiate analgesics for prostate cancer pain within 4  weeks before day  1.   
7. History of another invasive cancer within 3 years before screening, with the exception of fully treated cancers with a remote probability of recurrence.  The medical monitor and 
investigator must agree that the possibility o f recurrence is remote for exceptions .   
8. Screening  
99mTc-MDP  bone scintigraphy showi ng a superscan .   
9. Vis
ceral (eg , lung, liver) metastatic disease (biopsy not necessary).  Adenopathy is 
allowed .   
10. Absolute neutrophil count < 1500/ÂµL, platelet count < 100,000/ÂµL, or hemoglobin < 6.2 mmol/L (<  10 g/dL) at screening.  Patients may not have received growth factors or 
blood transfusions within 7 days, inclusive, before obtaining the screening hematology values .   
11. Total bilirubin  â‰¥ 1.5 times the upper limit of norma l (ULN) (except patients with 
a diagnosis of Gilbertâ€™s disease) , or alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) â‰¥  2.5 times ULN at screening .   
12. Creatinine > 177 Âµmol/L (>  2 mg/dL) at screening .   
13. Albumin < 30 g/L (<  3.0 g/dL ) at screening .   
14. Current or previously treated brain metastasis or active leptomeningeal disease.   
15. History of seizure any  time in the past for any reason or any condition that may 
predispose to seizures.   
16. History of loss of consciousness or transient is chemic attack within 12  months before 
screening .   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 24 of 66 
17. Clinically significant cardiovascular disease , including the following: 
â€¢ Myocardial infarction within 6 months before screening 
â€¢ Unstable angina within 3  months before screening 
â€¢ New York Heart Association cl ass III or IV congestive heart failure, or a history of 
New York Heart Association class  III or IV congestive heart failure, unless a 
screening echocardiogram or multigated acquisition scan performed within 3 months 
before screening demonstrates a left ven tricular ejection fraction â‰¥ 50% 
â€¢ History of clinically significant ventricular arrhythmias (eg,  sustained ventricular 
tachycardia, ventricular fibrillation, torsades de pointes) 
â€¢ History of Mobitz II second -degree or third -degree heart block without a perma nent 
pacemaker in place 
â€¢ Hypotension as indicated by systolic blood pressure < 86 mm Hg at screening  
â€¢ Bradycardia as indicated by a heart rate < 45 beats per minute on the screening 
electrocardiogram ( ECG ) and physical examination  
â€¢ Uncontrolled hypertension a s indicated by a systoli c blood pressure > 170 mm Hg 
or a diastolic blood pressure > 105 mm Hg at screening  
18. Gastrointestinal disorder affecting absorption.   
19. Major surgery within 4 weeks before screening .   
20. Any concurrent disease, infection, or comorbid co ndition that interferes with the ability 
of the patient to participate in the trial; places the patient at undue risk; or complicates the interpretation of the data, in the opinion of the investigator or medical monitor.   
5 ENROLLMENT AND STUDY PROCEDURES  
Study enrollment and procedures are summarized in the following subsections.  The timing 
of all study procedures is also provided in the schedule of activities ( Appendix 2).   
5.1 Screening Period  
The screening period will be from day  -28 through day  -1.  Screening procedures are listed in  
Table 1.  Assessments not completed within the appropriate interval must be repeated.   
For the purposes of this study, there will be no day  0.   
5.1.1 Study Identification Numbers  
After obtaining informed  consent, s tudy site personnel will assign a study identification (ID) 
number to a potential study participant.   For patients who provide informed consent and subsequently do not meet eligibility criteria 
or withdraw consent, study site personnel should document the screen failure in the patientâ€™s 
source documents.  The documentation should include demographics  and medical history, 
the reason for screen failure, the eligibility criteria reviewed , and procedures performed.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 25 of 66 
5.1.2 Screening Visit Procedures  
At the screening visit, study site personnel must explain to potential study participants all 
aspects of the study , including all scheduled visits and activities.  Study site personnel must 
obtain signed informed consent before any study- specific procedures  are conducted, and 
must document the informed consent process in the patientâ€™s source documents.  Informed 
consent may be obtained before the  28-day screening period.   
Screening procedures are listed in  Table 1.  The investigator will assess and confirm the 
eligibility of each patient.  All s creening procedure results  and relevant medical history must 
be available before eligibility can be determined.  All inclusion criteria must be met and none 
of the exclusion criteria may apply.   No eligibility waivers will be granted.   
After a patient is screened and the investigator determines the patient is  eligible, study  site 
personnel will complete a n Enrollment Authorization Form and fax or email it to the medical 
monitor or designee to approve the enrollment in writing.    
Table 1: Screening Procedures  
Activity / Assessment / Timing  Comment  
General  All screening procedures must be performed within the 28 -day 
screening period  (see below for informed consent ).   
Informed consent  Must obtain informed consent before performing any 
study- specific procedures.  May obtain before the 28-day 
screening period.   
Ensure consent is on the current version of the form approved by the IRB.   
Study ID  Assign study  ID number  to patient.  
Medical history  Review any time after obtaining informed consent.    
Eligibility criteria including BPI (Short Form) and ECOG 
performance status  All inclusion criteria must be met and none of the exclusion 
criteria may apply per Section  4.   
Refer  to Appendix  1 for BPI  and Table  13 for ECOG .   
12-Lead ECG  Obtain per local practice and read locally to confirm eligibility.    
Technetium  Tc 99m 
medronate b one scintigraphy 
â†’ Perform within 28 days 
before d ay 1 Whole -body radionuclide bone scintigraphy to establish the 
presence of bone metastatic disease ; read locally .   
Send copy of image to the central imaging vendor  for archiving. 
CT or MRI of chest, abdomen, 
and pelvis  
â†’ Perform within 28 days 
before d ay 1 To establish the absence of visceral metastatic disease 
(adenopathy is allowed ).   
Complete physical examination  Measure vital signs (temperature, blood pressure,  and heart rate), 
weight , and height.    
Assess systems per standard of care at the study site.    

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 26 of 66 
Activity / Assessment / Timing  Comment  
Adverse event review  Record adverse events (nonserious and serious) occurring during 
screening on the medical history case report form and in the 
patientâ€™s source documents for any patient who subsequently meets eligibility criteria and proceeds to enrollment.  If the 
adverse event is serious, also record it on the adverse event case report form.   
Collect serious adverse event information from the time of signed 
informed consent  and report it per Section  8.3.5 .   
Concomitant medications review  Record all ongoing medications and those discontinued within 28 days before the visit.   
Enrollment Authorization  Form  Complete, sign, and fax or email the form to the medical monitor or designee at least 2  business days before the anticipated day  1 
visit, if possible .   
The patient may proceed to the day  1 visit when the medical 
monitor or designee approves by signed form or email correspondence.   
Local  Laboratory Evaluations   
Serum chemistry, hematology  Refer to analytes listed in Table  12.   
Testosterone   
PSA  
 
5.2 Treatment Period  
Day 1 is the day of the first dose of study drug .  Patients will return to the study site at 
week s 5, 13, 21, and every 8 weeks thereafter , unless study drug is permanently discontinued 
for reasons outlined in S ection  5.3.   
5.2.1 Visit Windows  
At each specified study visit, procedures will be performed according to the schedule of 
activities (Appendix 2).   
A study visit may be scheduled on any day within a specified study week.  For any given day 
within the study week, the visit window is  Â±7 days  (ie, 7 days before or after the given day) 
except for weeks  5 and 13 ( Â±3 days) .  There is no visit window for week 1, day  1.   
Study d rug supplies must be taken into account when scheduling visits during windows.  
Procedures for a given visit may be split across the window to allow for drug resupply and 
completion of study procedures.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 27 of 66 
5.2.2 Week  1, Day  1 
Day 1 procedures are listed in Table 2.  Study site personnel should ensure that a medical 
monitor-approved Enrollment Authorization Form is in the patientâ€™s file before proceeding 
with day 1 procedures.    
Table 2: Week  1, Day  1 Procedures  
Activity / Assessment  Comment  
General Activities   
Complete physical examination  May skip if performed within prior 3  days.   
Measure vital signs (temperature, blood pressure, and heart rate), 
and weight.   
ECOG performance status ( Table  13).   
Assess systems per standard of care at the study site.   
Adverse events review  Record adverse events that occurred during screening on the 
medical history case report form and in the patientâ€™s source 
documents .  Do not record such events on the adverse event case 
report form.   
Concomitant medications review  Record any new medications or changes in ongoing medications.   
Enzalutamide dispensing  
 Provide the patient with a 12-week supply.  Provide instructions 
for dosing, storage, and return of all bottles (used and unused) of 
study drug at future visits.   
Local Laboratory Evaluations   
Serum chemistry, hematology  May skip if performed within prior 3  days.   
Refer to analytes listed in Table  12.   
PSA  
Central Laboratory/Imaging Evaluations  Refer to laboratory and imaging instruction manuals for sample processing and imaging acquisition requirements.    
Circulating tumor cells  Collect blood sample predose and process per laboratory manual 
instructions .   
18F-NaF PET/CT imaging ( NaF-1) Perform predose.  
Must perform within 7  days before first dose of enzalutamide .   
Perform a second baseline scan on up  to 5 patients at each study 
site to assess reproducibility . 
 
5.2.3 Week  5 
The visit window is Â±3 days.  Drug supply must be taken into account if a window is used 
to schedule the next visit.   
Week  5 procedures are listed in Table 3.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 28 of 66 
Table 3: Week  5 Procedures  
Activity / Assessment  Comment  
General Activities   
Brief physical examination  Measure vital signs (temperature, blood pressure, and heart rate), 
weight, and ECOG performance status ( Table  13).   
Perform symptom -directed examination and investigate any new 
abnormalities.    
Adverse events review  Record any new or ongoing adverse events.    
Concomitant medications review  Record any new medications or changes in ongoing medications.    
Study drug accountability  Record study drug returned and remind patient to return all 
bottles (used and unused) at each future visit.   
Local Laboratory Evaluations   
Serum chemistry, hematology  Refer to analytes listed in Table  12.   
 
5.2.4 Week  13 
The visit window is Â±3 days .  Drug supply must be taken into account if a window is used 
to schedule the next  visit.    
Week  13 procedures are listed in Table 4.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 29 of 66 
Table 4: Week  13 Procedures  
Activity / Assessment  Comment  
General Activities   
Brief physical examination  Measure vital signs (temperature, blood pressure, and heart rate), 
weight, and ECOG performance status (Table  13).   
Perform symptom -directed examination and investigate any new 
abnormalities.    
Adverse events review  Record any new or ongoing adverse events.    
Concomitant medications review  Record any new medications or changes in ongoing medications.    
Enzalutamide dispensing (if applicable)  As appropriate according to PSA value.   Per PSA assessment 
below, patients with PSA values increased from baseline may 
discontinue study drug and have safety follow -up unless the 
investigator considers continuation of study drug to be beneficial.   
Provide the patient with an 8 -week supply.  Provide instructions 
for dosing, storage, and return of all bottles (used and unused) of study drug at future visits.   
Study drug accountability  Record study drug returned and remind patient to return all bottles (used and unused) at each future visit.   
Local Laboratory Evaluations   
Serum chemistry, hematology  Refer to analytes listed in Table  12.   
PSA Patients with PSA values increased from baseline may 
discontinue study drug and have safety follow -up unless the 
investigator considers continuation of study drug to be beneficial.    
Imaging Evaluations  Refer to imaging instruction manual for imaging acqu isition 
requirements.    
18F-NaF PET/CT imaging (NaF -2)  
 
5.2.5 Week  21 and Repeating Every 8 Weeks  
Visits repeat every 8 weeks (Â± 7 days) until criteria are met for permanent treatment 
discontinuation ( Section  5.3).  Drug supply must be taken into account if a window is used 
to schedule the next visit.  Assessments are performed at every visit or every other visit as 
noted. 
Week  21 procedures are listed in  Table 5.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 30 of 66 
Table 5: Week  21 and Repeating Every 8 Weeks Procedures  
Activity / Assessment / Timing  Comment  
General Activities   
Brief physical examination  
â†’ Perform every 16 weeks  
(Â± 7 days)  Measure vital signs (temperature, blood pressure, and heart rate), 
weight, and ECOG performance status (Table  13).   
Perform symptom -directed examination and investigate any new 
abnormalities.    
Adverse events review  Record any new or ongoing adverse events.    
Concomitant medications review  Record any  new medications or changes in ongoing medications.    
Enzalutamide dispensing (if applicable)  Provide the patient with an 8- week supply.  Provide instructions 
for dosing, storage, and return of all bottles (used and unused) of study drug at future visits.   
Study drug accountability  Record study drug returned and remind patient to return all bottles (used and unused) at each future visit.    
Local Laboratory Evaluations   
Serum chemistry, hematology  
â†’ Perform every 16 weeks  
(Â± 7 days)  Refer to analytes listed in Table  12.   
PSA  
 
5.2.6 Time of Third 18F-NaF PET/CT Imaging  (NaF -3) 
Patients with disease progression (Section  9.1.1.2 ) and those without progression at 2 years 
after treatment initiation will have a  third 18F-NaF PET/CT imaging and  other assessments .   
No 99mTc-MDP  bone scintigraphy is  requi red if bone disease progression was confirmed  
previously on bone scintigraphy obtained at investigator discretion.  If no bone disease 
progression was seen by 99mTc-MDP  bone scintigraphy before NaF-3, 99mTc-MDP  bone 
scintigraphy will be required at the time  of NaF -3.   
The procedures are listed in Table 6.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 31 of 66 
Table 6: Time of Third 18F-NaF PET/CT Imaging  (NaF -3) 
Activity / Assessment  Comment  
Central Laboratory/Imaging 
Evaluations  Refer to laboratory and imaging instruction manuals for sample 
processing and imaging acquisition requirements.    
Circulating tumor cells  Collect and process blood sample per laboratory manual instructions.   
18F-NaF PET/CT imaging ( NaF-3) Perform at the time of disease progression  defined in 
Section  9.1.1.2  and briefly, as follows : 
â€¢ PSA progression (increase of at least 25% and an absolute 
increase of at least 2.0  ng/mL above nadir) , 
â€¢ Radiographic progression  (bone or soft tissue) , or  
â€¢ Other clinically relevant progression .  
Or perform at 2 years after initiation of treatment for patients 
without progression.   
99mTc-MDP  bone scintigraphy Whole -body radionuclide bone scintigraphy.   
Send copy of image to the central imaging vendor  for archiving.  
Not required if bone disease progression was  confirmed  earlier 
on bone scintigraphy ordered by  the investigator.   If no bone 
disease progression was seen by 99mTc-MDP  bone scintigraphy 
befor
e NaF-3, 99mTc-MDP  bone scintigraphy will be required at 
the time of NaF-3.   
CT or MRI of chest, abdomen, and 
pelvis  Perform for suspicion of soft tissue disease progression (at investigator discretion) . 
Local Laboratory Evaluations   
PSA  
 
5.2.7 Unscheduled Visit s 
Unscheduled visits  may be performed any  time to assess or follow  up adverse events, to 
perform bone scintigraphy , at the patientâ€™s request, or at the investigatorâ€™s request.  The date 
and reason for the unscheduled visit must be recorded in the source documents.   
If an unscheduled visit is necessary to assess toxicity  or for suspected disease progression, 
then diagnostic tests may be performed based on investigator assessment as appropriate.   
Unscheduled visit procedures are listed in Table 7.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 32 of 66 
Table 7: Unscheduled Visit Procedures  
Activity / Assessment  Comment  
General Activities  Perform as needed  
Brief physical examination  Measure vital signs (temperature, blood pressure, and heart rate), 
weight, and EC OG performance status ( Table  13).   
Perform symptom -directed examination and investigate any new 
abnormalities.    
Adverse events review  Record any new or ongoing adverse events.    
Concomitant medications review  Record any new medications or changes in ongoing medications.    
Local Laboratory Evaluations   
Serum chemistry, hematology  Refer to analytes listed in Table  12.   
 
5.3 Permanent Treatment Discontinuation  
Permanent  treatment discontinuation is defined as cessation of study drug treatment 
administration .  Safety follow -up will be performed  per Section  5.4.   
Temporary  treatment interruption is not considered permanent discontinuation.  R egularly 
scheduled study visits will continue for patients b ased on their enrollment date when their 
treatment is interrupted any  time and restarted .   
The reasons that require patients to permanently discontinue  study drug treatment are as 
follows: 
â€¢ Adverse event or intercurrent illness :  Any intolerable adverse event that cannot be 
ameliorated by the use of adequate medical intervention or that in the opinion of the 
investigator or medical monitor would lead to undue risk if study treatment were continued.  Refer to Section  
8.3.1.   
â€¢ Gross noncompliance with protocol :  The medical monitor or investigator may 
request permanent treatment discontinuation in the event of a major protocol 
deviation, lack of cooperation, or noncompliance .   
â€¢ Administration of prohibited concomitant therapy:  Refer to Section  7.2.  NOTE:  
Patients who discontinue due to administration of a prohibited concomitant therapy will remain in the study and  complete safety follow -up assessments per Section  
5.4.   
â€¢ Laboratory  abnormality defined as follows, unless the cause is identified and 
satisfactorily addressed , and the abnormality subsequently improves:   
â€“ Creatinine > 354 Âµmol/L (> 4.0 mg/dL)  
â€“ AST, ALT, or total bilirubin > 5- times the ULN  
â€“ Absolute neutrophil count â‰¤  750/ÂµL 
â€“ Platelet count <  50,000/ÂµL 
â€¢ Seizure:  Regardless of resolution of any identified etiology.   
â€¢ Death  

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 33 of 66 
â€¢ Loss to follow-up:  Refer to Section  5.5.   
â€¢ Sponsor discontinuation of study :  The sponsor reserves the right to terminate the 
study any time  for any reason  as described in Section  13.6.  The sponsor will 
terminate this study following completion of the study objectives, or earlier if deemed 
necessary .   
â€¢ Patient decision:  Patien ts may permanently discontinue study drug treatment any  
time for any reason.  Following permanent treatment discontinuation, patients should have protocol-required safety follow- up assessments approximately 30 days after the 
last dose of study drug or before initiation of cytotoxic chemotherapy, a lutamide (bicalutamide, nilutamide, or flutamide), or a new investigational therapy  (whichever 
occurs first),  unless the patient specifically declines further follow -up.  Study site 
personnel must document the patientâ€™ s decision in the source documents.  The most 
specific reason possible for treatment discontinuation should be recorded on the case report form .  â€œWithdrawal of consentâ€ should be entered only as a last resort.    
5.4 Safety Follow- Up 
All patients will have safety follow -up after permanent discontinuation of study drug 
(enzalutamide).  Safety follow -up should occur approximately 30 days after the last dose 
of study drug or before initi ation of cytotoxic chemotherapy, a lutamide (bicalutamide, 
nilutamide, or flutamide), or a new investigational therapy, whichever occurs first .  In the 
event that one of these treatment s is initiated before safety follow -up occurs (eg,  a physician 
not associated with protocol MDV3100-18 initiates the treatment, an d study site personnel 
are not aware of the treatment until afterward ), safety follow-up should be scheduled as soon 
as possible.   
If treatment is discontinued due to an adverse event or serious adverse event, the event(s) must be followed up as described in Section  8.3.6.  For patients who refuse further clinic 
study visits, telephone contact should be attempted and documented to review for adverse events through approximately 30 days after the last dose of s tudy drug or before initiation of 
cytotoxic chemotherapy, a lutamide (bicalutamide, nilutamide, or flutamide), or a new investigational therapy , whichever occurs first .  There is no long- term follow -up phase.   
Safety follow -up procedures are listed in  Table 8.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 34 of 66 
Table 8: Safety Follow- Up Procedures  
Activity / Assessment  Comment  
General Activities   
Complete physical examination  Measure vital signs (temperature, blood pressure, heart rate) and 
weight.   
ECOG performance status ( Table  13).   
Assess systems per standa rd of care at the study site.   
Adverse events review  Record any new or ongoing adverse events.  
Concomitant medications review  Record any new medications or changes in ongoing medications.  
Study drug accountability  Collect all remaining study drug and record study drug returned .   
Local Laboratory Evaluations   
Serum chemistry, hematology  Refer to analytes listed in Table  12.   
PSA  
 
5.5 Loss to Follow-Up 
Every r easonable effort should be made to contact any patient apparently lost to follow -up 
during the course of the study to complete study- related assessments , record  outstanding 
data, and retrieve study drug.   
Following unsuccessful telephone contact, an effort to contact the patient by mail using 
a method that provides proof of receipt should be attempted.  Alternate contacts are permissible if the patient is not reachable ( eg, primary care providers, referring physician, 
relatives) .  Such efforts should be documented in the patientâ€™s source documents.   
If all efforts fail to establish contact, the patient will be considered lost to follow-up.   
6 INVESTIGATIONAL PRODUCT INFORMATIO N 
6.1 General Information 
The study drug  is enzalutamide.  Enzalutamide  (Xtandi) is approved in the US and other 
regions to treat men with metastatic CRPC who have previously received docetaxel.   
The sponsor will provide e nzalutamide  capsules .  Patients who did not have a bilateral 
orchiectomy  will receive LHRH analogue therapy per standard of care.   
6.2 Enzalutamide Product Characteristics  
Enzalutamide , also known as MDV3100, has the chemical name 4-{3- [4-cyano -3-
(trifluoromethyl)  phenyl]-5,5- dimethyl-4-oxo-2- sulfanylideneimidazolidin -1-yl}-2-fluoro -N-
methylbenzamide .  The drug substance is formulated in the surfactant caprylocaproyl 
polyoxylglycerides, or Labrasol.  The product will be supplied as white to off- white gelatin 

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 35 of 66 
capsules containing 40 mg of enzalutamide.9  The chemical properties and list of excipients 
are presented in the investigator brochure.   
6.2.1 Packaging of Enzalu tamide  
Enzalutamide s tudy drug is  packaged in bottles with induction- sealed child -resistant caps 
labeled with the study protocol number, contents, directions for use, storage directions, 
clinical trial statement, and sponsor name.    
6.2.2 Storage of Enzalutamide 
Enzalutamide s tudy drug should be handled and stored safely and properly in accordance 
with the study drug label.   
6.2.3 Directions for Administration  of Enzalutamide 
The daily dose of enzalutamide is 160 mg/day given in 4  capsules (40  mg each) by mouth.   
Patients  should self -administer enzalutamide by mouth once daily, with or without food.  
The capsules should be swallowed whole without chewing, dissolving, or opening them.   
Patients should not make up missed or vomited doses; dosing should resume on the ne xt 
calendar day unless otherwise instructed.   6.2.4 Directions for Dose Modification  of Enzalutamide 
Patients who experience a grade 3 or higher toxicity that is attributed to enzalutamide and 
cannot be ameliorated by the use of appropriate medical intervention may  interrupt treatment 
with enzalutamide for 1  week or until the toxicity grade improves to grade 2 or lower 
severity.  Following consultation with the medical monitor , study drug dosing may be 
restarted  at the original dose (160 mg/d ay) or a reduced dose (80 or 120 mg /day).   
If enzalutamide is coadministered with a strong CYP2C8 inhibitor, the dose of enzalutamide 
should be reduced to 80 mg once daily.  If coadministration of the strong CYP2C8 inhibitor 
is discontinued, the enzalutamide dose should return to the dose used before initiation of the 
strong CYP2C8 inhibitor.   
6.3 Treatment Compliance  
Accountability for the study drug capsules (enzalutamide)  will be performed to document 
compliance with the dosing regimens .  Patients will be asked to bring all used and unused 
study drug bottles to study visits.  Study site personnel must make reasonable efforts to 
obtain used and unused study drug bottles from patients who do not routinely return them at 
study site visits.   
Unreturned capsule s will be considered to have been taken.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 36 of 66 
7 PRIOR AND CONCOMITANT THERAPY  
Prior and concomitant medications include all vitamins, herbal remedies, and 
over-the-counter and prescription medications.   
7.1 Prior Therapy  
Medications taken within 4  weeks before scr eening and any medications prescribed for 
chronic or intermittent use during the study, or dose adjustments of these medications, must 
be recorded on the case report form and in the patientâ€™s source documents.  The dosage and regimen of any chronic permitted concomitant medications should be stable during the screening period (â‰¥ 28 days before enrollment) and held constant throughout the study.   
Certain prior medications and therapies for prostate cancer are prohibited.  These include 
enzalutamide, abiraterone acetate, aminoglutethimide, ketoconazole, radium Ra 223 
dichloride or other bone-targeting radionuclides, or cytotoxic chemotherapy in the CRPC setting.  Patients who participated in a clinical study of an investigational agent that inhibits 
the androgen receptor or androgen synthesis are also excluded, unless treatment was placebo.    
Investigational agents are prohibited within 4 weeks before the screening visit.   
The following agents are prohibited within 4  weeks (28  days) before  day 1:  hormonal 
therapy (eg , androgen receptor inhibitors, 5-alpha reductase inhibitors), biologic therapy for 
prostate cancer (other than LHRH analogue therapy) , and opiate analgesics for prostate 
cancer pain .  However, these agents may be washed out (ie,  discontinued for 4 weeks) to 
qualify for the study if all other eligibility criteria are met.   Bone r adiation therapy to treat 
prostate cancer is also prohibited within 4 weeks before day  1.   
New treatment with denosumab,  bisphosphonates, or systemic corticosteroids for prostate 
cancer is prohibited within 4  weeks (28  days) before day 1.   
7.2 Concomitant Therapy  
Concomitant medications (including LHRH analogue therapy) will be assessed at all clinic 
visits.  All concomitant medications, including analgesic medications and opiates (including 
opioid-containing medications), must be recorded on the appropriate case report form.  If the use of any medication during the study is due to an adverse event, the adverse event must be recorded on the adverse event case report form and in the patientâ€™s source documents.   
Initiation of bisphosphonates or denosumab for any reason is prohibited following enrollment; however, t reatment with these agents may continue if initiated at least 4  weeks 
before enrollment.  Standard of care supplementation with calcium and vitamin D is encouraged.   
The following are prohibited during this study before NaF -3:   
â€¢ Initiation of cytotoxic ch emotherapy  

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 37 of 66 
â€¢ Radium Ra 223 dichloride or other bone-targeting radionuclide therapy 
â€¢ Other hormonal therapy, including but not limited to commercially available 
enzalutamide (Xtandi), abiraterone acetate, androgen receptor inhibitors, 5- alpha 
reductase inhibitors, or (if for prostate cancer) ami noglutethimide, ketoconazole, or 
systemic corticosteroids for prostate cancer  
â€¢ Biologic therapy (other than LHRH analogue therapy)  
â€¢ Radiation therapy to bone 
â€¢ Participation in another interventional c linical study of an investigational agent  
Another therapy may be used in combination with enzalutamide after NaF-3 with the 
approval of the investigator and sponsor, except for cytotoxic chemotherapy, antiandrogen therapy (eg,  bicalutamide, nilutamide, or flutamide), or another investigational agent.  Study 
drug treatment must be permanently discontinued and patients will have safety follow-up 
before initiation of one of these prohibited treatments.   
The following treatments are allowed:   
â€¢ Blood transfusions and growth factor support per standard of care and institutional 
guidelines 
â€¢ Corticosteroids for indications other than prostate cancer  
â€¢ Pain therapy per standard of care and institutional guidelines 
Deviation from these guidelines should occur only if it is absolutely necessary for the 
well-being of the patient  and does not jeopardize the analysis of the study endpoints, and 
must follow discussion and agreement between the investigator and the medical monitor , 
who will  determine the patientâ€™s suitability for continued treatment with study drug.   
7.3 Potential Interactions Between the Test Products and Concomitant Medications  
7.3.1 Enzalutamide  
7.3.1.1 Effects of Enzalutamide on Exposure to Other Drugs  
Clinical data indicate that enzalutamide is a strong inducer of CYP3A4 and a moderate 
inducer of CYP2C9 and CYP2C19 ( Section  1.2.1).  Concomitant use of enzalutamide with 
drugs with a narrow therapeutic index that are metabolized by CYP3A 4 (eg,  alfentanil, 
cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus), CYP2C9 (eg,  phenytoin, warfarin), and CYP2C19 (eg,  S-mephenytoin ) should 
be avoided if possible as enzalutamide may decrease their exposure.  If coadministration with warfarin cannot be avoided, additional INR monitoring should be conducted at  local 
laboratories .   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 38 of 66 
7.3.1.2 Drugs That May Affect Exposure to Enzalutamide 
7.3.1.2.1 Drugs That Inhibit or Induce CYP2C8  
Coadministration of a strong CYP2C8 inhibitor (eg, gemfibrozil) increased the composite 
AUC 0-âˆž of enzalutamide plus its active metabolite in healthy volunteers by 2.2 -fold 
(Section  1.2.1); therefore, coadministration of enzalutamide with strong CYP2C8 inhibitors 
should be avoided if possible.  If coadministration of enzalutamide with strong CYP2C8 
inhibitors cannot be avoided, the enzalutamide dose should be reduced to 80 mg once daily.  If coadministration of the strong inhibitor is discontinued, the enzalutamide dose should be returned to the dose used before  initiation of the strong CYP2C8 inhibitor.   
The effects of CY P2C8 inducers on the PK of enzalutamide have not been evaluated in vivo.  
Coadministration of enzalutamide with strong or moderate CYP2C8 inducers (eg, rifampin) 
may alter the plasma exposure of enzalutamide and should be avoided if possible.  Selection of a concomitant medication with no or minimal CYP2C8 induction potential is recommended.   
7.3.1.2.2 Drugs That Induce CYP3A4  
The effects of CYP3A4 inducers on the PK of enzalutamide have not been evaluated in vivo.  
Coadministration of enzalutamide with strong CYP3A4 inducers (eg, carbamazepine, 
phenobarbital, phenytoin, rifabutin, rifampin, rifapentine) may decrease the plasma exposure of enzalutamide and should be avoided if possible.  Selection of a concomitant medication with no or minimal CYP3A 4 induction potent ial is recommended.  Moderate 
CYP3A4 inducers (eg, bosentan, efavirenz, etravirine, modafinil, nafcillin) and St. Johnâ€™s wort may also reduce the plasma exposure of enzalutamide and should be avoided 
if possible.   
7.4 Precautions Regarding Concomitant Medications  
Refer to the following websites for updated lists of CYP inhibitors, inducers, and substrates: 
â€¢ http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ 
DrugInteractionsLabeling/ucm093664.htm#potency  
â€¢ http://medicine.iupui.edu/c linpharm/ddis/table.aspx   
8 SAFETY CONSIDERATIONS  
Study assessments of safety include adverse events, clinical laboratory tests, physical examinations, and vital signs.   
In the following sections, the sponsorâ€™s safety monitoring procedures are described 
(Section  8.1).  Adverse events are discussed in detail in the context of patient management, 
study drug dose modification, and safety reporting requirements, including follow-up procedures ( Sections  8.2 and 8.3).  Clinical laboratory safety tests are presented 

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 39 of 66 
(Section  8.4).  The study procedures for physica l examinations  and vital signs are also 
provided ( Section  8.5).   
8.1 Safety Monitoring 
The sponsor will periodically monitor safety data during the clinical study in addition to 
reviewing individual safety case reports, by examining the incidence and severity of adverse events and serious adverse events, changes in laboratory results, and other data (such as aggregate analysis of data from other enzalut amide studies ).  Any relevant safety concerns 
will be communicated to the investigators and regulatory agencies, as appropriate.   
8.2 Special Safety Considerations 
8.2.1 Study Drug Dose Modification Due to Adverse Event  
The instructions for modifying the dose of study drug due to an adverse event are provided 
in Section  6.2.4 for enzalutamide.   
8.2.2 Overdose Management 
The medical monitor must be contacted in the event of a stu dy drug overdose.   
An overdose is defined as any dose greater than the protocol-specified dose of enzalutamide 160 mg  once daily.  In the event of an overdose, treatment with study drug should be stopped 
and general supportive measures initiated, taking into consideration the half- life is  5.8 days 
for enzalutamide.  Patients may be at increased risk of seizures following an overdose of enzalutamide.  There is no known antidote to overdose.   
All overdose events are to be reported  as events of special interest  within 24 hours of 
awareness by the study site according to Section  8.3.5, whether or not the event meets 
adverse event criteria.   
8.2.3 Contrac eption  
A patient must use a condom if having sex with a pregnant woman .  Patients must not donate 
sperm from first dose of study drug through 3 months after the last dose of study drug.   
A patient and his female partner of childbearing potential must use 2 acceptable methods of 
birth control (1 of which must include a condom as a barrier method) from screening through 3 months after the last dose of study drug.  The 2 acceptable methods of birth control are as follows: 
1. A condom (barrier method is required) 
AND 
2. One of the following is required:   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 40 of 66 
â€¢ Established and ongoing use of oral, injected, or implanted hormonal method by the 
female partner  
â€¢ Placement  of an intrauterine device or intrauterine system by the female partner  
â€¢ Additional barrier method including contraceptive sponge or  occlusive cap 
(diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository  
by the female partner  
â€¢ Tubal ligation in the female partner  performed at least 6  months before screening 
â€¢ Vasectomy or other procedur e resulting in infertility (eg,  bilateral orchiectomy) 
performed  at least 6 months before screening 
8.3 Adverse Event  Definitions and Reporting  
8.3.1 Adverse Event Definitions  
Definitions are provided in this section for adverse events, events of special interest, serious adverse events, treatment -emergent adverse events, suspected unexpected serious adverse 
reactions  (SUSAR s), and unexpected adverse events.   
Adverse events :  An adverse event is any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not related to the study drug.   
Examples of adverse events include the following:   
â€¢ A change, excluding minor fluctuations, in the nature, severity, frequency, or duration of a pre-existing condition 
â€¢ Development of an intercurrent illness during the study 
â€¢ Development of symptoms that may or may not be related to the use of a concomitant medication or investigational product 
â€¢ Injury or accidents:  if a medical condition is known to have caused the injury or 
accident, the medical condition and the accident should be reported as 2 separate medical events (eg,  for a fall secondary to dizziness, both â€œdizzinessâ€ and â€œfallâ€ 
should be recorded separately)  
â€¢ Investigatio nal abnormalities (eg,  laboratory parameters, vital signs, ECG data) 
should be defined as adverse events only if the abnormality meets one of the following criteria:   
â€“ Induces clinical signs or symptoms  
â€“ Needs active intervention  
â€“ Needs interruption or discontinuation of study medication 
â€“ Abnormality or investigational value is clinicall y significant in the opinion 
of the investigator 

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 41 of 66 
An adverse event does not  include the following:   
â€¢ Medical or surgical procedures (eg, surgery, endoscopy, tooth extraction, 
transfusion); the condition that leads to the procedure is an adverse event 
â€¢ Pre-existing diseases or conditions present or detected before  the start of study drug 
administration that do not worsen 
â€¢ Situations where an untoward medical event has not occurred ( eg, planned 
hospitalization for an elective procedure as known at the time of informed consent) 
Events of special interest:  Adverse events of special interest are any events identified for 
intensive monitoring during the study.  For MDV3100-18, events of special interest include overdose ( Section  
8.2.2)  and pregnancy in the partner ( Section  8.3.7).   
Serious adverse events:  Any adverse event that meets any of the criteria in  Table 9  as 
determined by the investigator or sponsor.   
Table 9: Criteria for Serious Adverse Events  
Criterion  Comment  
Results in death  Death is an outcome, not an adverse event.  The 
primary adverse event resulting in the death 
should be identified.    
Is life threatening (immediate risk of death from 
the adverse event as it occurred)  Does not include an event that  hypothetically 
might have caused death if it were more severe.    
Results in or prolongs an existing inpatient hospitalization  For hospitalizations for surgical or diagnostic procedures, the illness leading to the surgical or diagnostic procedure will be identified as the serious adverse event (not the procedure).    
Results in persistent or significant incapacity or 
substantial disruption of the ability to conduct 
normal life functions  Permanent or substantial disruption of a personâ€™s 
ability to conduct normal life functions.    
Results in a congenital anomaly/birth defect   
Important medical events which jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above  Examples  include drug -induced bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions  
that do not result in inpatient hospitalization, and the development of drug dependency or drug 
abuse .   
Source:  US C ode of Federal Regulations:  21  CFR  312.32 [75  FR 59961]  
 
Treatment -emergent adverse events :  Adverse events observed following administration of 
the study drug.   
Suspected unexpected serious adverse reactions (SUSARs) :  Adverse events assessed as 
serious, related, and unexpected.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 42 of 66 
Unexpected adverse events :  Adverse events for which the nature or severity is not consistent 
with the reference safety information.   
8.3.2 Adverse Event Reporting  
To elicit adverse event reports from patients, the study site personnel should question the 
patient in a general way without suggesting specific symptoms.   
All patients who experience an adverse event will be evaluated at appropriate time intervals until the event resolves or stabilizes.  At the conclusion of the study, the investigator and 
medical monitor will assess unresolved adverse events and determine if additional follow-up is warranted as described in Section  8.3.6.   
All adverse events, whether or not related to the study drug, must be fully and completely 
documented on the adverse event case report form and in the patientâ€™s clinical record.  In addition, any adverse event resulting in permanent treatment discontinuation must be 
recorded on the treatment discontinuation case report form as well as documented in the patientâ€™s clinical record.  Adverse event terms should include a diagnosis or u nderlying 
cause, as available, in preference to listing the individual signs and symptoms.  If the diagnosis is not known, the investigator should record each sign and symptom as an individual adverse event.   
8.3.2.1 Adverse Event Reporting Periods  
Collection and reporting of adverse event information will begin at the time the patient signs informed consent for serious adverse events and from the first dose of study drug for nonserious adverse events, and will continue through 30 days after the last dose of study drug 
treatment or before initiation of cytotoxic chemotherapy, a lutamide (bicalutamide, 
nilutamide, or flutamide), or a new investigational therapy , whichever occurs first .  
Additional reporting instructions for serious adverse events and events of speci al interest are 
provided in Section  8.3.5.   
All adverse events from the time of the first dose of any study drug treatment must be documented on t he adverse event case report form and in the patientâ€™s  clinical record.  Any 
event occurring during screening must be documented on the medical history case report form and in the patientâ€™s clinical record for any patient who subsequently meets eligibility  
criteria and proceeds to treatment .   
8.3.3 Assessment of Causal Relationship  
The investigator will assess the relationship of an adverse event to study drug according to the criteria in Table 10 and document the relationship in the patientâ€™s source documents.   
Adverse events considered in the relationship categories of â€œPossibleâ€ or â€œProbableâ€ should be considered â€œadverse events wh ose relationship to the study drugs could not be ruled out.â€   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 43 of 66 
Table 10: Criteria for Determining Causal Relationship to Study Drug  
Relationship  Criteria  
Not Related  A clinical event, including laboratory test abnormality, with a temporal relationship 
to drug administration that makes a causal relationship improbable, and/or in which 
other drugs, chemicals, or underlying disease provide plausible explanations.  
Possible  A clinical event, including laboratory test abnormality, with a reasonable time 
sequence to administration of the drug, but that could also be explained by 
concurrent disease or other drugs or chemicals.  Information on drug withdrawal may be lacking or unclear. 
Probable  A clinical event, including laboratory test a bnormality, with a reasonable time 
sequence to administration of the drug, unlikely to be attributed to concurrent disease or other drugs or chemicals, and that follows a clinically reasonable 
response on re -administration (rechallenge) or withdrawal (dech allenge).  
 
8.3.4 Assessment of Severity ( Intensity) 
Severity describes the intensity of a specific adverse event (mild, moderate, or severe).  The 
particular event may be of relatively minor medical significance (such as severe headache).  
Severity is not the same as â€œserious,â€ which is based on patient/event outcome or action criteria.   
Inves tigators will grade the severity of adverse events according to the National Cancer 
Institute Cancer Therapy and Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE), version 4.  For terms not specified within the CTCAE, the criteria 
in Table 11 should be used to determine grade.   
Adverse event severity should be recorded in the appropriate section of the adverse event case report form and in the patientâ€™s source documents.   
Table 11: Criteria for Determining the Severity (Intensity) of an Adverse Event  
Grade  Intensity or  Severity  Clinical Description  
1 Mild  Asymptomatic or mild symptoms, clinical or diagnostic 
observations only; intervention not indicated  
2 Moderate  Minimal, local, or noninvasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living  
3 Severe or medically significant  Not immediately life -threatening ; hospitalization or prolongation of 
hospitalization indicated; disabling; limiting self -care activities of 
daily living  
4 Life-threatening  Life-threatening consequences; urgent intervention indicated  
5 Death  Death related to adverse event  
Source:  Common Terminology Criteria for Adverse Events v4.0  
 

0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
6HULRXV$GYHUVH(YHQWDQG(YHQWRI6SHFLDO,QWHUHVW5HSRUWLQJ
6WXG\VLWHSHUVRQQHOZLOOFROO HFWDQGUHFRUGVHULRXVDGYHUVHHY HQWVRQWKHDGYHUVHHYHQWFDVH
UHSRUWIRUPIURPWKHWLPHWKHSD WLHQWVLJQVWKHLQIRUPHGFRQVHQ WIRUPWKURXJKVFUHHQIDLOXUH
RUGD\VDIWHUWKHODVWGRVHRI VWXG\GUXJWUHDWPHQWRUEHIRU HLQLWLDWLRQRIF\WRWR[LF
FKHPRWKHUDS\DOXWDPLGHELFDO XWDPLGHQLOXWD PLGHRUIOXWDPLG HRUDQHZLQYHVWLJDWLRQDO
WKHUDS\ZKLFKHYHURFFXUVILUVW 6HULRXVDGYHUVHHYHQWVUHSRUW HGWRWKHLQYHVWLJDWRUDIWHUWKH
VDIHW\UHSRUWLQJSHULRGVKRXOGEH UHSRUWHGWRWKHVSRQVRULIWK HLQYHVWLJDWRUDVVHVVHVWKHHYHQW
DVUHODWHGWRWKHVWXG\GUXJ
8VLQJDVHULRXVDGYHUVHHYHQW UHSRUWIRUPDOOVHULRXVDGYHUVH HYHQWVDQGHYHQWVRIVSHFLDO
LQWHUHVWPXVW EHUHSRUWHG ZLWKLQKRXUV RIWKHVWXG\VLWHSHUVRQQH OÂ¶VNQRZOHGJHRIWKH
HYHQWUHJDUGOHVVRIWKHLQYHV WLJDWRUDVVHVVPHQWRIWKHUHODWLR QVKLSRIWKHHYHQWWRVWXG\GUXJ
WRWKLVFRQWDFW
1DPH
)D[ 86
%DFNXS)D[ 8QLWHG.LQJGRP
(PDLO 
3KRQH 
7KHLQLWLDOUHSRUWVKRXOGLQFOXGH DWPLQLPXPWKHIROORZLQJ 
x6WXG\QXPEHU0'9
x6LWHQDPHDQGQXPEHU
x,QYHVWLJDWRUQDPH
x3DWLHQWVWXG\,'QXPEHUVH[DQGDJH
x'HWDLOVRIVWXG\GUXJDGPLQLVWUDWLRQ
x7KHGDWHRIWKHUHSRUW
x$GHVFULSWLRQRIWKHVHULRXVDGYH UVHHYHQWRUHYHQWRIVSHFLDO LQWHUHVWHYHQWWHUP
VHULRXVQHVVRIWKHHYHQW
x&DXVDOUHODWLRQVKLSWRWKHVWXG\GUXJ
,IWKHSDWLHQWGLHGWKH UHSRUWVKRXOGLQFOXGHWKHFDXVHRIGHD WKDVWKHHYHQWWHUPZLWKIDWDO
RXWFRPHDQGZKHWKHURUQRWWKHG HDWKZDVUHODWHGWRVWXG\GUXJ DVZHOODVWKHDXWRSV\
ILQGLQJVLIDYDLODEOH
&ODULILFDWLRQLQ5HS RUWLQJRI6HL]XUHV
6HL]XUHFRQYXOVLYHRU QRQFRQYXOVLYHLVDOZ D\VUHSRUWHGDVDV HULRXVDGYHUVHHYHQWPPD
PPD
PPD
PPD
PPD
Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 45 of 66 
8.3.5.2 Clarification in Reporting of Deaths 
Death is not an adverse event but is an outcome of an adverse event.  For this protocol, 
reports of death without an adverse event will be managed as expedited reports (SUSARs) until the sponsor receives additional information.   
8.3.5.3 Clarification in Reporting of Disease Progression as an Adverse Event 
Disease progression is not unexpected in this study population and the term â€œdisease 
progressionâ€ should not be reported as an adverse event unless a more specific clinical term is not defined or available.  When clinical disease progression is identified, the clinical event that identifies the disease progression, if known, should be reported as the adverse event.   
8.3.6 Follow-U p of Serious and Nonserious Adverse Events  
All adverse events reported during the study should be followed at appropriate intervals until 
resolution, or until the event has stabilized, reached a new baseline, or (if enzalutamide is 
discontinued) a new antineoplastic treatment is initiated (all follow- up results are to be 
reported to the sponsor or designee).   
Adverse events that remain unresolved at the conclusion of the study may continue to be 
monitored if warranted based on clinical assessment by the investigator and medical monitor.   
Patients should be contacted by phone and written requests as appropriate for adverse event 
follow-up if they do not come to the clinic for safety follow -up as specified in Section  5.4.   
8.3.7 Pregnancy  Reporting Procedure  
If a study participant impregnates his partner following the first dose of study drug through 
3 months after permanent discontinuation of study drug treatment, the study participant 
should report the pregnancy to the investigator.  The investigator will report the pregnancy to the sponsor in the same timeframe as a serious adverse event ( Section  8.3.5).  The sponsor 
will provide forms to the investigator for use in reporting.  The expected date of delivery or expected date of the end of the pregnancy, last menstruation, estimated conception date, pregnancy result, and neonatal data, etc, should be included in this information.   
The investigator will follow the medical status of the mother, as well as the fetus, and will 
report the outcome to the sponsor.   
8.4 Clinical Laboratory Safety Tests  
Routine clinical laboratory safety tests ( hematology, serum chemistry ) will be performed 
according  to the schedule of activities ( Appendix 2) , as will PSA  and testosterone tests .  
Samples will be stored until the specified analyses are completed and then they will be 
destroyed in accordance with standard laboratory practice and ap plicable local regulations.    

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 46 of 66 
A list of the required routine clinical laboratory safety tests is provided in Table 12.  All 
samples for laboratory an alysis must be collected, prepared, labeled, and shipped according 
to laboratory requirements.   
All clinical laboratory safety tests will be performed by the local laboratory specified in 
Form  FDA 1572 Section  4.  The local laboratory reference ranges will be used.   Eligibility 
at screening will be based on local laboratory assessments.   
A different clinical laboratory may be used for unscheduled visits or for urgent care.  Such 
laboratory data will not be entered into the study database and these local laboratories will 
not be included on the FDA 1572 form.   
Table 12: Clinical Laboratory Safety Tests  
Hematology  Chemistry  
Hematocrit  
Hemoglobin 
Mean corpuscular volume  
Platelet count  
Red blood cell count  
White blood cell count with differential  Albumin  
Alkaline phosphatase  
ALT (alanine aminotransferase)  
AST (aspartate aminotransferase) 
Blood urea nitrogen and creatinine  
Ca++ 
Creatine phosphokinase  
Glucose  
Lactate dehydrogenase  
Magnesium, phosphate  
Na+, K+, total CO 2 (bicarbonate), Cl- 
Total bilirubin  
Total protein  
 
8.5 Physical Examinations, Vital Signs, and Electrocardiograms 
The investigator will perform complete or brief physical examinations according to the 
schedule of activities (Appendix 2) .   
Complete physical examinations  will be per standard care at the study site and may include 
dermatologic, cardiac, respiratory, lymphatic, gastrointestinal, musculoskeletal, and neurologic systems, and other systems if clinically indicated by symptoms .  Weight will be 
measured as part of the examination.  Height will be measured only at screening.   
Brief physical examinations  will be directed toward  patient -reported symptoms and include 
investigating any new abnormalities .  Weight will be measured as part of the examination.   
Vital sign measurements  will include temperature, blood pressure, and heart rate.   
Standard 12- lead ECGs  will be obtained and read locally for study el igibility purposes.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 47 of 66 
9 ASSESSMENT OF EFFICA CY AND SAFETY ENDPOINTS  
9.1 Assessment of Efficacy  
9.1.1 Assessment s for the Primary and Secondary Efficacy Endpoints 
The assessment for the primary and secondary efficacy endpoint s will include 
18F-NaF PET/CT imaging  and assessment of disease progression .   
9.1.1.1 18F-NaF PET/CT Imaging  
18F-NaF PET/CT imaging will be performed during the study as follows :   
â€¢ NaF-1: Following screening, within 7  days before first dose  
â€¢ NaF-2:  At week  13 
â€¢ NaF-3: At the time of PSA, radiographic (bone or soft tissue), or other clinically 
 relevant progression, or at 2 years without progression after treatment 
 initiation  
Up to 5 patients at each study site will have a second baseline scan to assess reproducibility 
of the scans at each study site.   
18F-NaF PET/CT imaging will be performed according to the procedures detailed in the 
imaging instruction manual  and interpreted at the central imaging vendor .   
9.1.1.2 Assessment of Disease Progression  
The assessment of disease progression will include PSA, radiographic (bone and soft tissue ), 
and other clinically relevant events as follows:  
PSA progression triggering NaF -3 will be defined as an increase of at least 25% AND an 
absolute increase of at least 2.0  ng/mL above nadir.   
Bone disease progression will be  defined as the appearance of at least 2  new lesions after 
screening assessed by 99mTc-MDP  bone scintigraphy.  Progression at week  13 or earlier will 
require a confirmatory 99mTc-MDP  bone scintigraphy at least 6 weeks later showing at least 
2 additional new lesions related to prostate cancer  (compared with the previous scan) .  After 
week  13, no confirmation of progression will be required if at least 2  new lesions related to 
prostate cancer are observed .   
Soft tissue  disease will be assessed by CT or MRI obtained at investigator discretion.  
Radiographic progression for soft tissue disease will be defined by RECIST 1.1.7   
Other clinically relevant events  of progression will be determined by the investigator and 
may include, but are not limited to , significant bone pain or skeletal -related events.   

0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
CCI
0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
(&2*3HUIRUPDQFH6WDWXV$VVHVVPHQWV
(&2*SHUIRUPDQFHVWDWXVDVVHVV PHQWVDUHUHTXLUHGWRDVVHVVSDWL HQWIXQFWLRQDOVWDWXVIRU
VWXG\HOLJLELOLW\SXUSRVHVDQGZLOOEHSHUIRUPHGWKURXJKRXWWKH VWXG\DFFRUGLQJWRWKH
VFKHGXOHRIDFWLYLWLHV $SSHQGL[ 'HWDLOVRIWKHDVVHVVPHQ WDUHVKRZQLQ7DEOH
7DEOH(&2*3HUIRUPDQFH6WDWXV$VVHVVPHQWV
6FRUH 'HVFULSWLRQRI )XQFWLRQDO6WDWXV
 )XOO\DFWLYHDEOHWRFDUU\RQDOOSUHGLVHDVHSHUIRUPDQFHZLW KRXWUHVWULFWLRQ
5HVWULFWHGLQSK\VLFDOO\VWUHQXRXVDFWLYLW\EXWDPEXODWRU\DQG DEOHWRFDUU\RXWZRUNRIDOLJKW
RUVHGHQWDU\QDWXUHHJOLJKWKRXVHZRUNRIILFHZRUN
$PEXODWRU\DQGFDSDEOHRIDOOVHOIFDUHEXWXQDEOHWRFDUU\RXW DQ\ZRUNDFWLYLWLHV8SDQG
DERXWPRUHWKDQRIZDNLQJKRXUV
 &DSDEOHRIRQO\OLPLWHGVHOIFDUHFRQILQHGWREHGRUFKDLUP RUHWKDQRIZDNLQJKRXUV
 &RPSOHWHO\GLVDEOHG&DQQRW FDUU\RQDQ\VHOIFDUH7RWDOO\ FRQILQHGWREHGRUFKDLU
 'HDG
6RXUFH2NHQHWDO 

67$7,67,&$/0(7+2'6$1' 6$03/(6,=('(7(50,1$7,21
6WDWLVWLFDODQG$QDO\WLFDO3ODQV
$VWDWLVWLFDODQDO\VLVSODQZLOOSUHVHQWWKHGHWDLOHGVWDWLVWLF DOPHWKRGVDQGDQDO\VHVIRU
WKLVVWXG\
$QDO\VLV3RSXODWLRQV
7KHLQWHQWWRWUHDWSRSXODWLRQLV GHILQHGDVDOO SDWLHQWVHQURO OHGLQWKHVWXG\DQGZLOOEH
XVHGIRUDOOHIILFDF\DQDO\VHV XQOHVVRWKHUZLVHVSHFLILHG
7KHVDIHW\SRSXODWLRQLVGHILQHGD VDOOSDWLHQWVZKRUHFHLYHDQ \DPRXQWRIVWXG\GUXJ
7KHVDIHW\SRSXODWLRQZLOOEHXVH GIRUDOOVDIHW\DQDO\VHV
(IILFDF\$QDO\VHV
7KHSULPDU\HIILFDF\HQGSRLQWDQDO\VLVZLOOLQFOXGHSDWLHQWVZK RXQGHUJR1D)DQG1D)
)1D)3(7&7LPDJLQJ 

CCI
Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 50 of 66 
Table 14: Definition of Terms for NaF Uptake Measures  
Term  Definition  
SUV total Total NaF uptake, which represents the tumor burden across all (global) bone lesions  or 
in individual lesions  reflecting bone -metastatic prostate cancer 
SUV hetero Heterogeneity of NaF uptake, which represents heterogeneity of lesion activity  
SUV mean Mean NaF uptake, which represents the average activity of all lesions  
SUV max Maximum NaF uptake, which represents the activity of the most aggressive lesion  
N Total number of lesions, which represents a numerical sum of all lesions  
VF Volume fraction, which represents the fraction of skeletal involvement  
 
10.3.1 Primary Efficacy Endpoint Analysis 
The primary efficacy endpoint is the proportion of patients with at least 1 responding bone 
lesion ( defined as a lesion with an SUV total less than at baseline ) on the third 
18F-NaF PET/CT scan (NaF -3) performed for each patient.  This assessment will be  triggered 
by any of the following events:   
â€¢ PSA progression ( an increase of at least 25% AND an absolute increase of at least 
2.0 ng/mL above nadir)  
â€¢ Bone disease progression ( the appearance of at least 2  new lesions after screening 
assessed by 99mTc-MDP  bone scintigraphy ) 
â€¢ Soft tissue disease progression defined by RECIST  1.17 
â€¢ Clinically relevant progression (eg , significant bone pain or a  skeletal -related event)  
â€¢ At 2 years without progression after treatment initiation  
10.3.2 Secondary Efficacy Endpoint Analysis 
The secondary efficacy endpoint is the heterogeneity of response across all bone lesions as determined by the global SUV
hetero at the time the primary endpoint is determined for each 
patient.  The global SUV hetero score is a measure of the heterogeneity of tumor activity across 
all bone lesions and is defined as follows, where g  = global, l  = lesion, N  = number of bone 
lesions.   
 
In other words, the global SUV hetero score is the sum of the squares of the differences 
between the SUV mean for each bone lesion and the global SUV mean, divided by the number 
of lesions.  Thus, a higher global SUV hetero score reflects more heterogeneity in bone lesion 
activity.   

0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
CCI
0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
6DIHW\$QDO\VHV
$OOVDIHW\DQDO\VHV ZLOOEHSHUIRUPHGXVLQJ WKHVDIHW\SRSXODWL RQ
6DIHW\DQDO\VHVZLOO EHVXPPDUL]HG6DIHW\ ZLOOEHHYDOXDWHGE \WKHLQFLGHQFHRIVHULRXV
DGYHUVHHYHQWVLQFLGHQFHDQGVHY HULW\RIDGYHUVHHYHQWVLQFLG HQFHRISHUPDQHQWWUHDWPHQW
GLVFRQWLQXDWLRQGXHWRDGYHUVHHY HQWVDQGLQFLGHQFHRIQHZFOL QLFDOO\VLJQLILFDQWFKDQJHVLQ
FOLQLFDOODERUDWRU\YDOXHVDQGYLWDOVLJQV
7KHWUHDWPHQWHPHUJHQWSHULRGL VGHILQHGDVWKHGXUDWLRQRIWLP HIURPWKHGDWHDQGWLPHRI
WKHILUVWGRVHRIVWXG\GUXJWUH DWPHQWHQ]DOXWDPLGHWKURXJK GD\VDIWHUWKHODVWGRVHRI
VWXG\GUXJWUHDWPHQWSHUPDQHQ WWUHDWPHQWGLVF RQWLQXDWLRQRUW KHGD\EHIRUHLQLWLDWLRQRI
F\WRWR[LFFKHPRWKHUDS\DOXWDPLGHELFDOXWDPLGHQLOXWDPLGHR UIOXWDPLGHRUDQHZ
LQYHVWLJDWLRQDOWKHUDS\ZKLFKHYHURFFXUVILUVWCCI
Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 53 of 66 
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA) and tabulated by system organ class and by preferred term within each system organ class.  Tabular summaries will include the incidence ov erall (number and percentage 
of patients with treatment -emergent  adverse events classified by system organ class and 
preferred term); incidence by intensity (severity graded according to the CTCAE , version 4), 
causality, seriousness, and outcome (eg, leading to discontinuation of study drug); and other presentations as appropriate.    
Serious adverse events occurring before study treatment will be tabulated separately if considered related to study procedure.   
Patient s with  the same adverse event reported more than once will be  counted once at the 
maximum severity or strongest relationship to study drug.   
Toxicity for labo ratory parameters  (hematology , serum chemistry) will be graded  using the 
CTCAE , version 4 when applicable .  Shift tables will be provided as appropriate for each 
parameter to summarize baseline toxicity grade versus postbaseline toxicity grade.  For each 
laboratory parameter that is not gradable by the CTCAE, a shift table based on the normal 
range (low, normal, and high) will be provided to summarize baseline result versus postbaseline result.  For each laboratory parameter, the baseline laboratory value i s defined 
as the last laboratory value collected on or before  the date of the first dose of study drug.   
10.5 Other Analyses  
Exposure:  The dose and cumulative dose of enzalutamide (mg) will be summarized with 
descriptive statistics:  n, mean, standard deviation, median, and range.   
Treatment compliance:  Will be measured by  the number of capsules taken during the entire 
study divided by the expected number of capsules, multiplied by 100%.    
10.6 Determination of Sample Size  
The total number of patients to be included in this study is approximately 20  and is based on 
practical clinical considerations.   
11 STUDY COMMITTEES AND COMMUNICATIONS  
No formal study committees are planned for this study .   
12 LABORATORY REQUIREMENTS  
Clinical laboratory safety sample s (hematology, serum chemistry ) will be analyzed locally as 
described in Section  8.4, as will the samples for testosterone (screening only) and PSA  for 
this study .  These samples should be collected according to local laboratory requirements.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 54 of 66 
13 INVESTIGATOR AND ADMINISTRATIVE  REQUIREMENTS  
Before initiating the study, the investigator must provide the following documents to the 
sponsor: 
â€¢ Fully executed and signed Form FDA 1572 
â€¢ Fully executed clinical trial agreement  
â€¢ Current  curriculum vitae ( also applies to all subinvestigators listed on the 
Form  FDA 1572) 
â€¢ Financial disclosure (also applies to all subinvestigators listed on the 
Form  FDA 1572) 
â€¢ Signed protocol signature page 
â€¢ Signed acknowledgment of receipt of the current Enzalutamide I nvestigator Brochure  
â€¢ Institutional review boa rd (IRB) approval letter 
â€¢ IRB-approved informed consent form 
â€¢ Additional documents as necessary per local requirements  
If an investigator changes during the course of the study, the sponsor and any local regulatory authorities, as applicable, must first appr ove the change of investigator and the new 
investigator must provide the sponsor all of the documents listed above.   
The s ponsor personnel or representatives  may  visit the study site , if necessary , before 
initiation of the study to review information with  study site personnel about protocol 
requirements pertaining to the study drug, case report forms, monitoring, serious adverse 
event reporting, and other relevant information.   
13.1 Ethics  
13.1.1 Institutional Review Board 
Before  initiating the study, the investigator will obtain confirmation from the IRB that the 
IRB is properly constituted and compliant with all require ments and  local regulations.   
The i nvestigator will provide the IRB with all appropriate material, such as the protocol, 
current Enzalutam ide Investigator Brochure , site -specific informed consent form , and other 
written information provided to the patients.  The study will not be initiated until the 
investigator obtains appropriate IRB approval in writing for  the protocol and informed 
consen t document, and copies are received by the sponsor .   
IRB approval will be obtained for any substantial protocol amendments and informed 
consent revisions before implementing the changes.  The investigator will provide 
appropriate reports on the progress of the study to the IRB, per local requirements, and 
to the sponsor or designee in accordance with applicable local  regulations.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 55 of 66 
13.1.2 Ethical Conduct of the Study  
This study will be conducted under the guiding principles of the World Medical Association  
Declaration of Helsinki, including current Good Clinical Practice (GCP) according to 
International Council for Harmonisation ( ICH) guidelines.  Specifically, this study is based 
on adequately performed laboratory and animal ex perimentation; the study will be conducted 
under a protocol reviewed and approved by an IRB; the study will be conducted by 
scientifically and medically qualified persons; the anticipated benefits of the study are in 
proportion to the risks; the rights and welfare of the patients will be respected; the physicians conducting the study do not find the hazards to outweigh the potential benefits; and each patient will provide written infor med consent before any protocol- specific tests or 
evaluations are performed.   
13.1.3 Patient Information and Informed Consent  
A properly executed, written informed consent, in compliance with the Declaration of Helsinki, ICH GCP, US  Code of Federal Regulations (CFR) for Protection of Human 
Subjects (21 CFR  50.25[a,b], CFR  50.27, and CFR  Part 56, Subpart A), and local 
regulations, will be obtained from each patient before entering the patient in  the trial.  The 
investigator or designee will prepare the informed consent form and provide the documents 
to the sponsor or designee for approval before submission  to the IRB .  The sponsor  and the 
IRB must approve the documents before the investigator implements them.   
The i nvestigator will provide copies of the signed informed consent form to each patient and 
will maintain th e signed original document within the patientâ€™s clinical record per local 
requirements .  The investigator will also fully document the informed consent process in the 
patientâ€™s source documents .   
13.1.4 Maintaining Patient Confidentiality  
All reports and patient samples will be identified only by a study ID number and actual 
initials (if permitted) or mock initials and date of birth (month/year only if no date is permitted) in order to maintain patient confidentiality.  Additional patient confidentiality issues are addressed in the clinical trial agreement and in the informed consent form signed by each study participant.   
13.2 Data Quality Assurance 
13.2.1 Data Management 
Clinical d ata management will be performed by the sponsor or designee according to 
procedures described in a comprehensive data management plan.  The data management plan 
will include procedures for processing the data from this study , and will describe the 
responsibilities of the sponsor and designee when  clinical data management is provided by 
an external  vendor.  In particular, the data management plan will include a list of the standard 
operating procedures that apply to this study.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 56 of 66 
Adverse events and medications will be coded using MedDRA and the World Health 
Organization Drug Dictionary (WHO -DD), respectively.  The dictionary versions will 
be named in the data management plan.    
13.2.2 Case Report Forms  
The study will use an electronic data capture system.  All elect ronic case report forms will 
be designed and provided electronically to the site by the sponsor or designee and electronic 
data capture system vendor.  All case report form books are to be filled out completely, 
reviewed , and signed by the investigator or subinvestigators listed on the Form FDA  1572 or 
other appropriate local health authority documents.   
13.2.3 Study Monitoring  
The sponsor or designee will monitor this study in accordance with current GCP guidelines.  
By signing this protocol, the investigator grants permission to the sponsor or designee and appropriate regulatory  authorities to conduct onsite monitoring of all appropriate study 
documentation.  T o ensure the accuracy of data collected on the case report forms, it is 
mandatory that sponsor representatives (eg, study monitor)  have direct access to original 
source documents ( eg, paper or electronic patient records, patient charts, and laboratory 
reports) needed to verify the entries on case report forms.  During the review of these documents, the anonymity of the patient will be respected with strict adherence to professional standards of confidentiality.   
A study monitor will contact and visit the site regularly and will be allowed, on request at 
a mutually acceptable time, to inspect the various  original medical records  (paper or 
electronic) related to  the study.  The study monitor will be responsible for inspecting the case 
report forms at regular intervals throughout the study, to verify the adherence to the protocol and the completeness and correctness of all case report form entries.  The investigator agrees to cooperate with the study monitor to ensure that any problems detected in the course of 
these monitoring visits are resolved .   
13.2.4 Study Audits  
During the course of the study and after study completion, it is likely that one or more quality assurance audits w ill be undertaken by authorized sponsor representatives.  The purpose of 
the audit is to ensure that the study is (or was) conducted and monitored in compliance with the protocol as well as recognized GCP guidelines and regulations.  These audits will also increase the likelihood that the study data and all other study documentation can withstand a regulatory authority inspection.  If such audits are to occur, they will be arranged for a reasonable and agreed upon time.  By signing this protocol, the investigator grants permission to the sponsor or designee to conduct onsite audits of all appropriate facilities and study documentation.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 57 of 66 
13.3 Investigational Product Accountability  
The investigator must maintain accurate records (including dates, quantities, and bottle 
identification numbers) of all study drug supplies received.  All records must be made 
available to the sponsor, authorized representatives, and appropriate regulatory agencies, 
upon request.   
Current ICH GCP guidelines require the investigator to ensure that study drug deliveries 
from the sponsor are received by a responsible person ( eg, pharmacist), and the following: 
â€¢ That such deliveries are recorded , for example, on the sponsorâ€™s drug accountability 
log or other sponsor-approved pharmacy log 
â€¢ That study drug is handled and stored safely and properly in accordance with the label 
and the study protocol 
â€¢ That study drug is only dispensed to study patients in accordance with the protocol 
â€¢ That any used or unused drug is returned by the patient at each required visit 
â€¢ That any unused study drug is returned to the sponsor- designated facility  or standard 
procedures for the alternative disposition of unused study drug are followed and only 
after approval by the sponsor representative 
Drug inventory and accountability records for the study drugs will be kept by the investigator/pharmacist.  Study drug accountability throughout the study must be documented.  The following guidelines are therefore pertinent:   
â€¢ The investigator agrees not to supply study drug to any persons except the patients in this study .   
â€¢ The investigator/pharmacist will keep the study drugs in a pharmacy or other locked 
and secure storage facility under controlled storage conditions as required by the study drug label , accessible only to those authorized by the investigator to dispense 
these study drugs .   
â€¢ The investigator/pharmacist will maintain a study drug inventory.  The inventory will 
include details of material received and a clear record of when they were dispensed 
and to which patient.   
â€¢ The investigator/pharmacist agrees to conduct a final drug supply inventory and to record the results of this inventory on the drug accountability record at the conclusion or termination of this study .  It must be possibl e to reconcile delivery records with 
those of used and returned study drug.  Any discrepancies must be accounted for.  Appropriate forms of deliveries and returns must be signed by the person responsible.   
â€¢ Used or unused study drug may be destroyed at the study site according to standard institutional procedures if the sponsor agrees with the procedure, and after drug accountability has been conducted by the sponsor or representative, unless otherwise approved.  A copy of the standard institutional procedure for destroying investigational drugs will be provided to the sponsor or designee upon request for review and approval before the first onsite destruction.  Unused study drug not 

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 58 of 66 
destroyed at the site must be returned to the sponsor-de signated facility at the end 
of the study or upon expiration.   
13.4 Compensation, Insurance, and Indemnity  
In the event of a side effect or injury, appropriate medical care as determined by the 
investigator or designated alternate will be provided.   
If bodily injury is sustained, resulting directly from the use of the study drug or by required 
study procedures, the sponsor will reimburse for reasonable physician fees and medical expenses necessary for treatment of only the bodily injury that  is not covered by the patientâ€™s 
medic al or hospital insurance, provided that the injury is not due to a negligent or wrongful 
act or omission by the study doctor and study staff.  No other compensation of any type will be provided by the sponsor.  Financial compensation for lost wages, disabi lity, or discomfort 
due to the study participation or procedures is not available.   
13.5 Retention of Records  
The investigator must make original study data (paper or electronic) accessible to the study 
monitor, other authorized sponsor representatives , and regulatory a gency  inspectors 
(eg, US FDA) upon request.  A file for each patient must be maintained that includes the 
signed informed consent form and copies of all source documentation related to that patient.  
The investigator must ensure the reliab ility and availability of source documents from which 
the information on the case report form was derived.   
Patient identity information recorded will be maintained for at least 15 years on the patient 
confidentiality log  or longer if required by local re gulation s.   
Investigators must maintain all study documentation for at least 2  years following the 
approval of the drug, or until 2  years after the investigational drug program is discontinued, 
or longer if required by local regulations.  Study documentation includes all essential 
documents as defined in ICH E6 Guidelines for Good Clinical Practice.  The sponsor or 
designee will notify the investigator when any records may be discarded , but investigators 
must comply with local regulations .   
13.6 Study Terminat ion 
The sponsor will terminate this study following completion of the study objectives, or earlier 
if deemed necessary.   
The sponsor reserves the right to terminate the study any time  for any reason .  When the 
sponsor is aware of information on matters concerning the quality, efficacy, and safety of the 
study drugs, as well as other important information that may affect proper conduct of the clinical study, the sponsor may terminate the study and send a written notice of the 
termination along with the reasons to the investigator.   

0HGLYDWLRQ,QF (Q]DOXWDPLGH 3URWRFRO0'9
'(&Â±),1$/  3DJHRI
,IDQLQYHVWLJDWRURUWKHLQYHVWLJ DWRUÂ¶V,5%LQWHQGVWRWHUPLQD WHSDUWLFLSDWLRQL QWKHVWXG\WKH
LQYHVWLJDWRUPXVWLPPHGLDWHO\ LQIRUPWKHVSRQVRUDQGSURYLGHWK HUHDVRQIRULW
86(2)678'<,1)250$7,21$1'38%/,&$7,21
7KHUHVXOWVRIWKLVVWXG\ZLOO EHSXEOLVKHGRUSUHVHQWHGDWVFL HQWLILFPHHWLQJVLQDWLPHO\
REMHFWLYHDQGFOLQLFDOO\PHDQLQJIXO PDQQHUWKDWLVFRQVLVWHQW ZLWKJRRGVFLHQFHLQGXVWU\DQG
UHJXODWRUJXLGDQFHDQGWKHQHH GWRSURWHFWWKHLQWHOOHFWXDOSU RSHUW\RI0HGLYDWLRQ 
UHJDUGOHVVRIWKHRXWFRPHRIWKH WULDO7KHGDWDJHQHUDWHGLQ WKLVFOLQLFDO
WULDODUHWKHH[FOXVLYHSURSHUW \RIWKHVSRQVRUVDQGDUHFRQILG HQWLDO:ULWWH QDSSURYDOIURP
WKHVSRQVRUVLVUHTXLUHGSULRUW RGLVFORVLQJDQ\LQIRUPDWLRQUH ODWHGWRWKLVFOLQLFDOWULDODQG
QRSXEOLFDWLRQVLQLWLDWHGE\LQYH VWLJDWRUVPD\EHSXEOLVKHGXQW LODOOSURWRFROGHILQHGSULPDU\
DQGVHFRQGDU\HQGSRLQWVDUHSXEOLV KHGLQDPDQXVFULSW(YHU\D WWHPSWZLOOEHPDGHWR
PLQLPL]HWKHLQWHUYDOEHWZHHQWKH FRPSOHWLRQRIGD WDDQDO\VLVD QGSXEOLFDWLRQRIWKHVWXG\
UHVXOWV5HFRPPHQGDWLRQVIRUWKH WLPLQJRISUHVHQWDWLRQRIWUL DOHQGSRLQWGDWDDQGWKH
SXEOLFDWLRQYHQXHVFRQJU HVVHVMRXUQDOVZLOO EHJLYHQE\WKHV SRQVRUÂ¶V3XEOLFDWLRQV6WHHULQJ
&RPPLWWHH
(DFKLQYHVWLJDWRUDJUHHVWRVXEPLWDOOPDQXVFULSWVRUFRQJUHVV DEVWUDFWVDQG
SRVWHUVSUHVHQWDWLRQVWRWKHV SRQVRUVSULRUWRVXEPLVVLRQ7KL VDOORZVWKHVSRQVRUVWRSURWHFW
SURSULHWDU\LQIRUPD WLRQSURYLGHFRPPHQWV EDVHGRQLQIRUPDWLRQ IURPRWKHUVWXGLHVWKDWPD\
QRW\HWEHDYDLODEOHWRWKHLQYH VWLJDWRUDQGHQVXUHVFLHQWLILF DQGFOLQLFDODFFXUDF\7KH
GHWDLOVRIWKHSURFHVVH VRISURGXFLQJDQGUHYLHZLQJUHSRUWVPD QXVFULSWVDQGSUHVHQWDWLRQV
EDVHGRQWKHGDWDIURPWKLVWUL DOZLOOEHSUHVHQWHGLQWKHLQYH VWLJDWRUÂ¶VFOLQLFDOVWXG\
DJUHHPHQW
,QDFFRUGZLWKVWDQGDUGHGLWRUL DODQGHWKLFDOSUDFWLFHWKHVSR QVRUVZLOOJHQHUDOO\VXSSRUW
SXEOLFDWLRQRIPXOWLFHQWHUWULDOV RQO\LQWKHLUHQWLUHW\DQGQR WDVLQGLYLGXDOFHQWHUGDWD,Q
WKLVFDVHDFRRUGLQDWLQJLQYH VWLJDWRUDQGOHDGDXWKRUZLOOEH GHVLJQDWHGE\PXWXDO
DJUHHPHQW
$Q\IRUPDOSXEOLFDWLRQRIWKHVW XG\LQZKLFKLQSXWRIVSRQVRUS HUVRQQHOH[FHHGHGWKDWRI
FRQYHQWLRQDOPRQLWRULQJZLOOEHF RQVLGHUHGDVDMRLQWSXEOLFDWL RQE\WKHLQYHVWLJDWRUDQGWKH
DSSURSULDWHVSRQVRUSH UVRQQHO$XWKRUVKLSZ LOOEHGHWHUPLQHGE \PXWXDODJUHHPHQWDQGDOO
DXWKRUVPXVWPHHWWKHFULWHULD IRUDXWKRUVKLSHVWDEOLVKHGE\WK H,QWHUQDWLRQDO&RPPLWWHHRI
0HGLFDO-RXUQDO(GLWRUV,&0-(8 QLIRUP5HTXLUHPHQWVIRU0DQXVF ULSWVRUVWULFWHUORFDO
FULWHULD7KHVSRQVRUVGRQRWFRPSHQVDWH IRUDXWKRUVKLSRIDSXEOLFDWLR QDQGDOODXWKRUV
ZLOOEHUHTXLUHGWRGL VFORVHDVSDUWRIWKHSXEOLFDWLRQVXEPLV VLRQDQ\SRWHQWLDO FRQIOLFWVRI
LQWHUHVWLQFOXGLQJSHUWLQHQWIL QDQFLDORUSHUV RQDOUHODWLRQVKL SVZLWKWKHVSRQVRUVRUUHODWHG
HQWLWLHVLQFOXGLQJVSRQVRUVRIF RPSHWLQJSURGXFWVWKDWPLJKWE HSHUFHLYHGWREHDVRXUFHRI
ELDV$XWKRUVKLSLVGHFLGHGRQD QLQGLYLGXDOEDVLVDQGWKHVSR QVRUÂ¶V3XEOLFDWLRQV6WHHULQJ
&RPPLWWHHDQGVSRQVRUUHSUHVHQWDWLY HVZLOOPXWXDOO\GHWHUPLQHD XWKRUVDQGWKHLUVHTXHQFH
RQLQGLYLGXDOSXEOLFDWLRQVEDVHGRQW KHUHODWLYHFRQWULEXWLRQR IHDFKDXWKRUWRWKHVWXG\
DQGRUSXEOLFDWLRQPPD
Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 60 of 66 
Investigators in this study agree to have their name listed as an investigator in any 
publication reporting results from this study, whether or not they are an author on the publication.   
Professional medical writing support is permissible, and any writin g support will be 
acknowledged in each applicable publication, explaining the role the professional writer had 
in the drafting of the publication.  Medical writing and publications support funded by the sponsors on behalf of investigator authors will be considered as a transfer of value under the 
reporting requirements of the Patient Protection Affordable Care Act:  Physician Payment 
Sunshine Provision.
12  Transfer of value will be allocated to authors following sponsor 
guidelines.   

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 61 of 66 
15 REFERENCES  
1. Czernin  J, Satyamurthy N, Schiepers C. Molecular mechanisms of bone 18F-NaF deposition. 
J Nucl  Med. 2010 Dec;51(12);1826-9. 
2. Moris son C, Jeraj  R, Liu  G. Imaging of castration- resistant prostate cancer: development of 
imaging response biomarkers. Curr  Opin  Urol. 2013 May;23(3):230-6. 
3. Kurdziel KA, Shih   JH, Apolo  AB, Lindenberg L, Mena E, McKinney YY, et  al. The kinetics 
and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. 
J Nucl  Med. 2012 Aug;53(8):1175-84. 
4. Alom  M, Aleksic I, Ruhle B, Iannot ta P, O keefe C, Mouraviev  V, et  al. Accuracy of NaF 
PET/CT scan to detect bone metastases in CRPC. Abstract presented at: 2014  Genitourinary 
Cancers Symposium; 2014 Jan  30-Feb 01; San Francisco,  CA. (abstract 186).  
5. Iagaru  A, Young P , Mittra  E, Dick  DW, Herfkens R, Gambhir  SS. Pilot prospective evaluation 
of 99m Tc -MDP scintigraphy, 18F  NaF  PET/CT, 18F FDG PET/CT and whole-body MRI for 
detection of skeletal metastases. Clin  Nucl  Med. 2013 Jul;38(7):e290-6. 
6. Scher  HI, Fizazi  K, Saad  F, Taplin  ME, Sternberg  CN, Miller  K, et  al. Increased survival with 
enzalutamide in  prostate cancer after chemotherapy. N  Engl  J Med. 
2012 Sep  27;367(13):1187-97. 
7. Eisenhauer  EA, Therasse  P, Bogaer ts J, Schwartz LH, Sargent  D, Ford  R, et  al. New  response 
evaluation criteria in  solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 
2009 Jan;45(2):228-47. 
8. Vanderhoek  M, Perlman  SB, Jeraj  R. Impact of different standardized uptake value measures on 
PET-based quantification of treatment response. J Nucl  Med. 2013 Aug;54(8):1188 -94. 
9. Xtandi (enzalutamide) capsules. Northbrook (IL): Astellas Pha rma US, Inc.; 2012 Aug. 
Package insert.  
10. Oken  MM, Creech  RH, Tormey  DC, Hort on J, Davis  TE, McFadden  ET, et  al. Toxicity and 
response criteria of the Eastern Cooperative Oncology Group. Am J Clin  Oncol. 
1982 Dec;5(6):649-55.  
11. International Committee of Medical Journal Editors (ICMJE). Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals  [Internet]. 
2013 Aug [cited 2014 Jul 15 ]. Available from: http://www.icmje.org  
12. 111th Congress. HR 3590 - Patient Protection and Affordable Care Act. Section 6002: Physician 
payment sunshine provision. In: gpo.gov [Internet]. 2010 [cited 2014 Jul 18]. Available from: 
http://www.gpo.gov/fdsys/pkg/BILLS-111hr3590pp/pdf/BILLS-111hr3590pp.pdf  

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 62 of 66 
16 INVESTIGATOR SIGNATURE  
MEDIVATION, INC.  
A Phase 2, Open- Label, Single -Arm Study of 18F-Sodium Fluoride PET/CT Bone Imaging 
in Enzalutamide -Treated Chemotherapy -NaÃ¯ve Patients With Bone- Metastatic 
Castration -Resistant P rostate Cancer  
Signature of Agreement for Protocol MDV3100- 18, Amendment 2, v3.0, 08 DEC  2016 
I have read this protocol and agree to conduct the study as outlined herein, in accorda nce 
with Good Clinical Practice  and the Declaration of Helsinki, and complying with the 
obligation s and requirements of clinical i nvestigators and all other requirements lis ted 
in 21 CFR  Part 312.  
   
Print Study Site Name   Study Site Number  
Print Investigator Name    
Investigator Signature   Date  
 

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 63 of 66 
Appendix  1: Brief Pain Inventory (Short Form)  
 

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL   Page 64 of 66 
 

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL  Page 65 of 66 
Appendix  2: Study Schedule of Activities  
Study Period  Screening  Treatment  Unsched [1]  Safety FUP [2] 
Study Week  âˆ’4 to âˆ’1  1 5 13 21 then  q8w Varies  Varies  Varies  
Study Days  -28 to -1 1 29 85 141 then q56d  na na na 
Window (Days) [3]  na na Â±3 Â±3 Â±7 na na na 
General Activities          
Informed consent , study ID number [4] X        
Medical history  X        
Eligibility criteria incl. BPI, ECOG  X        
12-lead electrocardiogram (local read)  X        
99mTc-MDP  bone scintigraphy  X [5]      X [6]    
CT or MRI of chest/abdomen/pelvis  X [5]      X [6]    
Complete physical examination [7]  X X [8]       X 
Brief physical examination [9]    X X X [10]  X  
Adverse events review [ 11] X X X X X  X X 
Concomitant medications review  X X X X X  X X 
Enzalutamide dispensing   X  X X    
Study drug accountability    X X X   X 
Enrollment authorization form [1 2] X        
Local Lab Evaluations          
Hematology, serum chemistry  X X [8] X X X [10]  X X 
Testosterone  X        
Prostate -specific antigen  X X  X [13] X X  X 
Central Lab/Imaging Evaluations [ 14]         
Circulating tumor cells   X [15]    X [16]   
18F-NaF PET/CT imaging   X (F-1) [17]  X (F-2)  X (F-3) [18]    
[1] Any time necessary to assess or follow up adverse events, at the patientâ€™s request, or per investigator decision.    
[2] Approximately 30 days after the last dose of study drug (permanent discontinuation) or before initiation of cytotoxic chemotherapy, a lutamide 
(bicalutamide, nilutamide, or flutamide), or  a new investigational therapy, whichever occurs first .   
[3] Drug s upply must be taken into account when scheduling visits during windows.  Visit procedures may be split across the window to a llow for drug 
resupply and completion of study procedures.    

Medivation, Inc.  Enzalutamide  Protocol MDV3100- 18 
08 DEC 2016 â€“ FINAL  Page 66 of 66 
[4] Must be before any study -specific procedures.  May obtain before the screening window.  Ensure consent is on the current version of the form.   
[5] Must be within 28 days before day  1.  Send copy of bone scintigraphy image  to the central  imaging vendor  for archiving .   
[6] At investigator  discretion ( eg, significant bone pain or a skeletal -related event  for 99mTc-MDP  bone scintigraphy; or suspicion of soft tissue disease 
progression for CT or MRI ) or (for 99mTc-MDP  bone scintigraphy only) to coincide with NaF-3 unless bone diseas e progression was confirmed earlier .  
Progression at week  13 or earlier will require a confirmatory 99mTc-MDP  bone scintigraphy at least 6  weeks later showing at least 2  additional new 
lesions related to prostate cancer (compared with the previous scan).  After week  13, no confirmation of progression will be required if at least 2  new 
lesions related to prostate cancer are observed.   If no bone disease progression was seen by  99mTc-MDP  bone scintigraphy before NaF -3, then 
99mTc-MDP  bone scintigraphy will be  required at the time of NaF-3.  Send copies of bone scintigraphy image s to the central imaging vendor  for 
archiving .   
[7] Includes vital signs (temperature, blood pressure, heart rate), ECOG performance status, weight.  Height at screening only.   
[8] May skip if performed within prior 3  days.   
[9] Symptom -directed and includes vital signs, ECOG performance status, and weight.   
[10] Repeats every 16  weeks Â±7 days after week  21.   
[11] Collect serious adverse event information from the time of signe d informed consent and nonserious adverse event information from the time of first 
dose of study drug through 30 days after the last dose or initiation of cytotoxic chemotherapy, a lutamide (bicalutamide, nilutamide, or flutamide), or a 
new investigational  therapy, whichever occurs first .  Phone patients for follow -up if they do not come to the clinic.    
[12] Complete, sign, and fax or email the form with requested items to the medical monitor or designee at least 2  business days before the anticipated day  1 
visit, if possible.  Patient may proceed to day  1 visit when medical monitor or designee approves by signed form or email correspondence.   
[13] Patients with PSA values increased from baseline may discontinue study drug and have safety follow -up unless the investigator considers continuation 
of study drug to be beneficial.   
[14] Refer to laboratory and imaging instruction manuals for sample processing and imaging acquisition requirements.  Interpretation of 18F-NaF PET/CT 
imaging performed at  the central imaging vendor .   
[15] Collect predose.  
[16] At time of NaF-3. 
[17] Perform predose.  Must occur within 7  days before first dose of enzalutamide.  Perform a second baseline scan on up to 5 patients at each study site to 
assess reproducibility . 
[18] At time of PSA, radiographic ( bone or soft tissue ), or other clinically relevant progression, or at 2 years without progression after treatment initiation.   
18F-NaF PET, 18F-sodium fluoride positron emission tomography; CT, computed tomography;  BPI, Brief Pain Inventory;  ECOG, Eastern Cooperative 
Oncology Group; 99mTc-MDP,  technetium  Tc 99m medronate; (F-1), (F -2), (F -3) designators for sequential 18F-NaF PET/CT imaging; FUP,  follow -up; lab, 
laboratory; ID, identification; MR I, magnetic resonance imaging; na, not applicable; q8w, every 8 weeks; unsched, unscheduled.    
 
